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INTRODUCTION
Background and purpose
During the years prior to the turn of the century, scientific and
medical attention for genetic disorders was mainly focused on under-
standing rare single-gene disorders, such as Huntington’s disease,
Duchenne muscular dystrophy, and cystic fibrosis (CF), as well as
chromosomal abnormalities. The medical specialty of clinical genetics
was established in the 1980s and 1990s in many European countries to
diagnose these kinds of rare disorders and to counsel patients and
families.
In recent years, the attention of the genomics and genetics research
community has shifted toward understanding the basis of common
complex disorders. Common diseases are diseases frequently encoun-
tered in health care. Some cases of common disorders are character-
ized by a strong influence of germline mutations in a single gene; these
will be referred to as ‘monogenic subtypes’. In many cases common
disorders have a multifactorial etiology: they are caused by several
genes and environmental factors, involving gene–gene and/or gene–
environment interactions. We will use the term ‘complex disease’
to indicate diseases with variable etiology, including multifactorial
etiology as well as monogenic subsets. When discussing ‘susceptibility
genes’ in this document, we refer to genetic variants with low
predictive value. We need to admit, however, that no generally
accepted threshold for categorizing predictive value levels exists.
Researchers nowadays study the myriad of genetic polymorphisms
that have been identified during and since the Human Genome
Project. The spectacular growth of genome-wide association studies1
has shed new light on which of these variants represent risk factors for
common diseases. Understanding the pathogenesis and etiology, and
finding new ways to prevent and treat those diseases are major
challenges. The traits or diseases under study include coronary artery
disease, myocardial infarction, stroke, peripheral artery disease, obe-
sity, type 1 diabetes, type 2 diabetes, breast cancer, cervical cancer,
colorectal cancer, prostate cancer, celiac disease, bipolar disorder,
Crohn’s disease, and many more. Should incorporation of these
research results into current clinical and public health practice become
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possible, then researchers and practitioners have to be prepared for the
way in which this changes their daily routine.2–8
The clinical management of information about frequently occurring
DNA variants that lead to moderate increases in risks for common
diseases requires a different approach from that of the significantly
increased genetic risks for numerous rare health problems. Translation
of research findings to useful health-care applications appears to be
lagging behind. Implementation of useful research findings may take
years or decades. Meanwhile, some applications of very limited clinical
utility have become available directly to the consumers. Difficulties
with the translation of research findings need to be understood and
addressed if genetics and genomics research is to fulfil its promises
towards improving diagnosis, treatment, and prevention. Currently
(in 2010) the genetics research community is skeptical about the
possibilities of genetic susceptibility testing and screening contributing
significantly to the improvement of the quality of health care. The
implementation in health care of genetic tests that are considered
useful should overcome several thresholds.
Health promotion and disease prevention for the population at
large has been the domain of public health professionals; yet, public
health approaches have thus far not taken into account genetic risk
factors and often not even family history.9 So far, advice on lifestyle,
physical activity, and nutrition has been developed in a one-size-fits-
all approach.6 The era of genomics presents the promise of persona-
lized prevention and drug treatment, which has been met with
enthusiasm by many people, but called into question by others.10
In the light of these new developments in research, there is a
pressing need to assess the possibilities for and implications of genetic
testing and screening in common diseases (pertaining to multifactorial
disorders as well as monogenic subtypes) from both a clinical and a
societal perspective. As with genetic testing in rare mendelian dis-
orders, these assessments should comprise analytic validity, clinical
validity, clinical utility, and ethical, legal and social issues,11,12 as well
as health economic aspects. Should a genetic test for a common
disease have sufficiently high clinical utility in a specific setting, and
should implementation in health care be potentially worthwhile, then
the framework for its implementation has to be determined: clinical
genetics, medical specialist care, primary care, as a genetic screening
program, or as a commercial offer. Currently, as far as common
disorders are concerned, testing for monogenic subtypes has mainly
been implemented in health care.
In Europe, a shared understanding of and opinion about these
developments needs to be established among human and clinical
geneticists to enable them to inform future policy making by the
European Union (EU) and member states. For this purpose, informa-
tion was gathered in a background document as input for an expert
workshop in Seville, 8–10 October 2007, on ‘Clinical validity and
utility of genetic susceptibility testing in common disorders’.
In reflecting on the shift in the field of research from rare
monogenic to common disorders with a genetic component, this
document is a follow-up on several documents and initiatives that
have aimed at documenting and harmonizing genetic testing services
in Europe.13–20 Because of shared interests and complementary
expertise, it is a collaborative initiative of three parties: the Public
and Professional Policy Committee (PPPC) of the European Society of
Human Genetics (ESHG), EuroGentest, and the Institute for Pro-
spective Technological Studies (IPTS). The PPPC is involved in setting
professional standards for human and clinical genetics and in issuing
recommendations for national and European policy regarding genetic
services. EuroGentest is a EU-funded Network of Excellence (NoE)
that aims at the standardization and harmonization of genetic testing
services and at improving the overall quality of genetic services offered
within the EU. This includes both the establishment of procedures and
guidelines for the validation of methods and technologies and
the provision of quality-assured information sources to medical
professionals, as well as proper utilization of genetic services. The
IPTS is one of the seven scientific institutes of the European Commis-
sion’s Joint Research Centre (JRC). It informs EU policy making on
issues with a socioeconomic and a scientific or technological dimension.
After the Seville workshop, to enable further discussion on some
genetic epidemiological issues, a workshop was organized in Septem-
ber 2008 in Amsterdam. The background document was revised into
its present form on the basis of comments by participants of both
meetings and other experts, some of whom are active in the EU-
funded Public Health Genomic European Network (PHGEN, http://
www.phgen.eu) project and the international GRAPH-Int (http://
www.graphint.org) consortium that was established under the Cana-
dian Public Health Agency. These organizations have been established
to promote, at both the European and the global level, responsible and
effective translation of genome-based knowledge and technologies
into public policy and public health services.
Suggestions were incorporated in the background document, and
during the process the PPPC discussed the recommendations. A draft
of the background document and recommendations were distributed
and posted on the web during the summer of 2009 to elicit further
comments. After this procedure the draft was revised. The PPPC and
the Board of the ESHG approved the final version. This final text is
expected to reflect the views of the European human genetics scientific
and professional community.
Scope and limitations
In this document we will discuss genetic testing and common
disorders from a health-care perspective. New possibilities for genetic
testing confront health-care workers with the question of whom to test
and which test to use. This document focuses on genetic testing and
screening in common disorders. The term ‘common disorder’ is used
for disorders that individually have a high impact on public health.
Examples of common disorders include cardiovascular disease (CVD),
stroke, diabetes, cancer, dementia, and depression. For a health-care
practitioner – unlike a geneticist or an epidemiologist – it may not be
clear whether a common disorder is due to one gene with a high risk of
serious disease, or due to a combination of several genes and several
environmental factors. For disorders in which both etiologies exist, both
monogenic and multifactorial, the etiology can be thought of as
‘complex’. Mendelian diseases can have a complex etiology too: one
major gene, many modifying genes, and a series of environmental
factors. This is not what we mean by ‘complex’ in the present document.
Common complex diseases are at present being redefined as a series
of diseases with similar symptoms but variable etiology: a few genes,
many genes, interactions between genes, many environmental factors,
etc. The main difference between ‘complex’ and ‘monogenic or
Mendelian’ is that in a Mendelian or monogenic disorder an alteration
in one gene is a prerequisite for passing the threshold to develop the
disorder, although the effect of the mutation could, in some cases, be
modulated by genetic variants in other genes or epigenetic events
caused by environment, life style, etc, while in complex disorders both
whether one will develop disease and the severity are modulated by the
complex etiology. In Mendelian diseases one crosses the threshold to
disease due to one gene; in complex diseases different factors are
needed for crossing the threshold. Between these two extremes there
are a series of combinations, for example, the BRCA1 or BRCA2 genes,
wherein carrying a mutation will bring an individual close to the
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threshold but other genes and/or environmental factors to push one
over it, that is, to cause disease (cancer in this case). Mendelian
diseases can be used as an example for common complex diseases, to
generate insights into etiological pathways and into avenues for the
potential implementation of specific programs in health care. For
common complex disorders, genetics and genomics research promises
to personalize medicine. Instead of a one-size-fits-all approach, the
disorders may be stratified to etiologically different subgroups that
also differ according to prognosis and response to treatment and
prevention. Lessons learned from rare monogenic conditions may help
tailor health care for common complex disorders. Personalizing or
tailoring health care will in practice often lead to stratified health care,
distinguishing between several groups, while treatment on an indivi-
dual level is rare.
Different definitions of ‘genetic’, ‘screening’, and ‘testing’ exist. For
the purpose of this document we will use genetic (susceptibility)
‘testing’ in a broad sense, while we use genetic (susceptibility) ‘screen-
ing’ for a systematic, proactive offer to members of a certain group of
individuals. Screening may be a well-organized public health program,
usually aiming at a low risk population. ‘Genetic’ testing will be
defined as the analysis of DNA or biomarkers for the evaluation of one
or more genetic risk factors for a particular disease or disease group.
In health care, genetic screening has to be distinguished from genetic
testing because the setting and implications are different. Genetic
testing traditionally is carried out on patients or family members
who, for whatever reason, have taken the initiative to seek professional
advice. Thus, in a health-care setting, testing may provide a health
professional with relevant information for diagnosis, prognosis, disease
management, and/or further treatment of an individual patient.
Genetic testing is also sometimes used in a broader, more compre-
hensive sense. Genetic tests may be used in genetic screening programs.
Genetic screening traditionally refers to explicit and systematic
programs directed either at whole populations of asymptomatic
individuals or at subpopulations in which risk is known to be
increased or in which the specific phase of life merits screening,
such as in the case of pregnant women or newborns. It may be relevant
to distinguish between different types of target groups and, further-
more, to distinguish between this systematic approach (eg, as in public
health programs) and the situation in which asymptomatic (or low-
risk) persons are offered a test (eg, on the internet). Just as in
screening, the recent possibilities for direct-to-consumer genetic test-
ing may be used by asymptomatic persons. Although these tests may
be chosen for recreational purposes (such as ancestry testing), they
may yield (sometimes unsought) medically relevant information.
Commercial genetic testing or screening may be aimed at a broad
range of disorders, ranging from traits and common disorders to rare
and serious disorders.
In some cases, however, also in the regular health-care setting of a
doctor–patient relationship, a more systematic offering of tests may be
introduced. This is the case when testing becomes a standard regime
for a certain patient group. Testing for mutations in breast cancer
tumor tissue provides a good example of such a systematic approach,
which can therefore be regarded as a form of genetic screening. In this
document, we will indicate specifically which aspects of screening
(such as low-risk group, systematic approach) are implied when we
refer to screening.
In genetic screening, tests may be offered to individuals by a health-
care agency or a physician, which may give the public the impression
that these tests are imposed upon people. The ethical dilemmas are
magnified and the responsibilities of the physicians are correspond-
ingly greater.21 The genetic nature of a disorder can result in risk
implications for the blood relatives of the screened person, even
though they may not have been included in the screening programs,
nor perhaps wish to be included.
When Wilson and Jungner22 formulated their classic list of screen-
ing criteria for the World Health Organisation (WHO) in 1968, the
possibility of offering treatment was deemed to be an essential
prerequisite for offering a sound screening program. Since then,
many refinements of these criteria have been formulated, for instance,
as regards treatability. Especially in the case of genetic screening, an
added aim may be to offer information and options regarding
reproductive choices, reducing risk by preventive measures such as
changing health behavior, or planning of life events.
Genetic screening for common complex disorders would ideally
offer options concerning preventive strategies related to lifestyle,
medication, or interventions such as regular monitoring (for example,
of biochemical markers in serum, such as cholesterol levels, monitor-
ing of organ function, detecting early premalignant changes, etc).
However, the discriminatory power of genetic screening to identify
who should or should not be offered particular lifestyle advice or
medical interventions remains disputed, especially for ‘susceptibility
genes’ that confer a low relative risk and have a low predictive value.
When using the term ‘susceptibility’ testing or screening, it can be
debated what level of risk might be implied.23 The definition in the
previous section does not refer to a specific level of risk. A clear-cut
distinction between susceptibility testing (indicating a moderately
increased risk) and predictive or presymptomatic testing (indicating
a severely increased risk) cannot be given. In principle, testing for
relatively high penetrant genes, such as BRCA1 or BRCA2 (indicating a
lifetime risk of developing hereditary breast cancer of between 60 to
85%), could be regarded as a form of susceptibility testing, and, most
notably, in the United States the term ‘susceptibility testing’ is also
used for these highly penetrant disorders. In practice, however, those
kinds of informative tests are considered to be on the predictive side,
pertaining to highly penetrant monogenic disorders and monogenic
subforms of common disorders, whereas the term ‘susceptibility
testing’ is reserved for relatively lower predictive values associated
with common disorders.
This document reviews and discusses current biomedical, epide-
miological, ethical, social scientific, public health, health economic,
and health technology assessment (HTA) literature on genetic testing
and screening in common disorders, as well as documentation on
regulatory and policy issues.
A search was performed in PubMed–medline and the Social Science
Citation Index using keywords relevant to genetic susceptibility and
testing or screening for common disorders. In addition, references
from relevant articles were selected. Especially reviews, reports, posi-
tion papers, and editorials were considered. Reports on HTAs con-
cerning genetic susceptibility testing were also used. For this purpose,
several databases accessible via the internet were surveyed and the
relevant literature on the topic of (economic) evaluation of testing
services was reviewed (see Appendix C).
Given the two poles of rare, often severe, monogenic disorders
caused by highly penetrant genotypes on the one hand and polygenic,
multifactorial (complex) common disorders associated with genotypes
of low penetrance on the other hand, this document focuses upon the
common disorders associated with genotypes of higher or low
penetrance: in particular, those conditions where the public health
implications need to be considered – that is, at which level of clinical
utility tests should be made available and how they should be
implemented in practice. For many common disorders, monogenic
subtypes exist, including certain forms of cancer (most notably colon
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cancer and breast and ovarian cancer). It appears worthwhile explor-
ing to what extent health-care practices developed for these disorders
may help identify challenges for the future implementation of knowl-
edge of the human genome into health care.24 Learning from health
care for monogenic disorders and monogenic subtypes may help to
decide on potential avenues of implementation or non-implementa-
tion in health care.
A limitation of this document is the absence or scarcity of
information on molecular pathways, population genetic data, test
performance, and social, psychological, ethical and health economic
data, and experience regarding susceptibility testing. Furthermore, the
settings in which tests are piloted or marketed are constantly changing.
As Calnan et al25 note: ‘New technologies rarely emerge fully formed
at their optimum effectiveness and lowest cost; rather they develop in
situation, as clinicians master new techniques and the existing
technology is tweaked and modified to suit the clinical contextythe
cost of a new technology may fall rapidly as development costs are
covered, uptake rates increase, and the healthcare provider reorganises
to provide the service more efficiently. All of this happens a consider-
able way down the implementation pathway.’ Therefore, the data we
could obtain for this background document may prove to be of
limited value. However, science progresses rapidly, and genome-wide
association studies are revealing associations between common dis-
orders and genetic variants at a fast pace, which urges a common
understanding of, and vision for, the possibilities of genetic testing and
screening in common complex disorders.
For this reason, we will make use of analogies with existing forms of
testing and screening, including testing and screening for monogenic
subtypes of common complex disorders, whenever this seems appro-
priate. Special cases such as hemochromatosis (monogenic, yet not
highly penetrant) and familial hypercholesterolemia (FH; monogenic,
highly prevalent, but only one out of many risk factors for CVD) will
also be discussed. The health care provided for these disorders in
various countries and health centers falls outside the scope of clinical
genetics, and could guide our thinking about future genetic testing
and screening in common complex disorders.
This document will not consider germline prenatal or preconcep-
tional testing, nor testing of biomarkers for tumor recurrence, but it
will discuss testing of mutations in tumor tissue, since this may reveal
susceptibility to certain forms of therapy. Also, pharmacogenomic
applications will not be discussed in depth, although some examples
will be given of pharmacogenomic testing.
Outline. In the next section, the terrain of common complex
disorders is introduced. Different assessment frames for genetic testing
and screening are discussed. The section following that examines the
aims and strategies for genetic testing and screening in common
disorders and discusses some examples of current testing and screen-
ing in Europe. The section ‘The economic evaluation of genetic tests’
discusses the cost–benefit relation of different types of tests and
screening strategies and how they could be used in the clinic in a
cost-effective way. The subsequent section addresses the ethical, legal,
and social issues of testing and screening in common disorders. The
last section addresses regulatory and intellectual property issues in the
EU as well as the United States.
COMMON DISEASES
In the second half of the last century, medical genetics was mainly
occupied with rare chromosomal disorders and monogenic condi-
tions, including inborn errors of metabolism, dysmorphic, and mental
retardation syndromes. The challenge in common complex diseases, as
recognized by clinical geneticists, was mainly to identify subtypes of
the diseases that were due to single gene mutations of high penetrance,
and to offer affected families the genetic services they need.16,17 While
the recent EuroGentest document on genetic testing services in
Europe13 concentrated on hereditary, mostly rare disorders, and on
the dominant role of clinical geneticists in their management, the
present documentation is concerned with the clinical validity and
utility of genetic tests for common complex disorders (both multi-
factorial and monogenic subtypes). When used either in the setting of
an individual doctor–patient relationship or in that of systematic
screening, these tests would interface with everyday medical practice,
impacting on the majority of clinical specialties and primary care.
In 2003, the ESHG stated that ‘beyond the rare Mendelian subsets,
genetic influences in common diseases are likely to be conditional on
the environment. Testing for these low penetrance susceptibility genes
is likely to be of limited clinical utility’. However, as is illustrated by
Figure 1, a clear distinction between Mendelian and ‘the remainder’ is
not possible. Firstly, most monogenic disorders are also affected by
modifier genes and environmental factors, and therefore are not as
simply ‘Mendelian’ as initially thought. For instance, for narcolepsy
the genetic factor HLADR2 antigen is necessary, but very few
individuals with that variant develop the disease.26 The same holds
for HLA-B27 carriers and ankylosing spondylitis.27 Some monogenic
disorders may only manifest in a specific environment; for instance,
the metabolic disorder phenylketonuria (PKU) will only cause sig-
nificant disease in the presence of a protein-containing diet, and in
G6PD deficiency hemolytic anemia occurs only if the affected indivi-
duals eat fava beans or take sulfonamides. In other instances, the
clinical picture of a monogenic disorder depends upon environmental
influences, such as bacterial (Pseudomonas aeruginosa) infections in
patients with CF. In most common diseases, the clinical manifestation
of any particular genetic factor is likely to be precipitated or modified,
to a variable extent, by other genetic or environmental factors. Bearing
this in mind, Figure 1 can help to understand different etiological
contributions of genetic and environmental factors. It should not be
regarded as a linear model.
Most, if not all, common diseases are etiologically heterogeneous:
different cases can be caused by different etiological factors. Often,
numerous genetic variants and multiple environmental factors have a
role.29–31 Different combinations of genetic factors and combinations
of genetic and environmental factors may be involved in the disease
history of different patients. In addition, rare major genes may be
Genetic load
Environmental effect
Genetically determined
highly penetrant
Monogenic subtypes
Incompletely penetrant
Polygenic
Environmental
Multifactorial
Figure 1 The genetic etiology of disease, a spectrum from ‘genetically
determined’ to ‘environmental’.
Source: Modified from Bomprezzi et al.28 Adapted by permission from BMJ
Publishing Group Limited. Copyright r 2003.
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relevant. Research into the genetic basis of common diseases is
increasingly focusing on all genes, not only on those causing Mende-
lian subforms. Approaches are becoming increasingly large-scale, and
hypothesis-driven studies are being replaced by hypothesis-generating
ones, such as genome-wide association studies. Instead of assessing
single-gene effects, future work will concentrate upon characterizing
complex and interacting pathways by means of systems biology. In
addition to the human (host) genome, the genomes of pathogens
(such as the malaria parasite), vectors (such as the Anopheles gambiae
mosquito), or model organisms (such as the mouse) are also being
studied.
Mortality and morbidity related to common diseases have a high
public health impact. Most deaths and hospital admissions in adults
are related to common diseases, and only few to rare diseases. The
medical specialties involved in common diseases are very diverse
(oncology, cardiology, rheumatology, etc). While clinical geneticists,
molecular geneticists, and cytogeneticists still focus mainly on the
domain of rare disorders, caused by highly penetrant mutations, their
role in the genetics of complex diseases is less clear. For most
clinicians, the genome era has not yet arrived.32 For genomics research
to also have an effect on clinical practice, health-care providers need to
become more literate in genomics. Building bridges between basic
researchers, genetic experts, and health-care professionals is therefore
of paramount importance.
Heritability reflects the proportion of inter-individual variation in
disease susceptibility in a population that is estimated to be due to
genetic variation. It is therefore a crude measure of the genetic
component of disease etiology. Heritability varies in different popula-
tions and is dependent on the assumptions made in the calculations,
which have been questioned by some authors.33–35 A heritability of 0.5
suggests that half of the variation in disease susceptibility in the
population may be explained by genetic variation. Heritability esti-
mates for some common diseases are given in Table 1. Owing to
formal and experimental imponderabilities, however, most of these
values should not be regarded as absolute.
For practical purposes, it may be useful to categorize common
diseases on the basis of organ manifestation or pathogenesis. The
International Classification of Diseases37 takes this approach, and many
HTA studies therefore start from disease categories such as ‘CVD’
(based on the organ system) or ‘cancer’ (based on the pathogenesis).
In nearly all common disease categories, one or more subgroups
can be identified – comprising at most 5–10% of all cases in the
population – which appear to be due to the action of single
major genes. They comprise the so-called ‘Mendelian subforms’ of
common diseases (see Table 2). However, it is important to bear in
mind that these rare, major gene mutations may have variable
penetrance.
Evaluations of the clinical validity and utility of genetic testing and
screening for these subsets should follow the same rules as recom-
mended for other Mendelian disorders.13 It should be borne in mind,
however, that the great majority of patients and families falling into
the Mendelian subgroup category of common disorders have not yet
been identified and properly dealt with.39 Recognizing this subset of
cases, for which meaningful genetic testing is indeed available and is of
proven utility, should be an important goal of public health genetics
education and practice.
Genetic contribution to disease etiology
The spectrum of diseases, ranging from genetically determined to
environmental (see Figure 1), comprises several etiological cate-
gories,40,41 such as, for example:
 monogenic (Mendelian): disease-causing single-gene mutation;
 chromosomal: numerical or morphological abnormalities, causing
disabilities of varying extent;
 multifactorial: combined effects of multiple genetic variants and
their interaction with a range of environmental factors (including
infectious diseases, for which the susceptibility, clinical course, or
effectivity of treatment may be influenced by genetic factors);
 exogenous or environmental.
‘Multifactorial’ and ‘complex’ etiologies are not completely synony-
mous. A disorder with a complex etiology may be both heterogeneous
in etiology (including monogenic subgroups or cases with a purely
Table 1 Examples of common disorders and their heritability
Multifactorial disease Heritability
Age-related maculopathy 0.45
Age-related macular degeneration 0.46–0.71
Crohn disease 1.0
Prostate cancer 0.42
Breast cancer 0.27
Type 2 diabetes 0.26
Obesity 0.40–0.54
Coronary artery disease (CAD) 0.49
Death from CAD 0.57a
0.38b
Hypertension 0.80
aMales.
bFemales.
Source: Modified from Lango and Weedon.36 Adapted by permission from John Wiley & Sons,
Inc. Copyright r 2008 (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2796).
Table 2 Examples of common diseases with Mendelian subsets
Common disease Mendelian subsets
Atherosclerosis Familial hypercholesterolemia due to low-density lipoprotein
(LdL) receptor mutations
Cirrhotic liver
disease
Hemochromatosis due to HLA-H gene mutations
Emphysema a1-antitrypsin deficiency
Diabetes Maturity-onset diabetes of the young (MODY) due to mutations in
(a) MODY 1 (hepatocyte nuclear factor-4a gene),
(b) MODY 2 (glucokinase gene)
(c) MODY 3 (hepatocyte nuclear factor-1a gene)
Breast cancer Autosomal dominant hereditary breast cancer due to mutations in
(a) BRCA1
(b) BRCA2
(c) p53
(d) PTEN
Colon cancer (a) Familial adenomatous polyposis coli (FAP) due to APC
mutations
(b) Hereditary non-polyposis coli (HNPCC) due to mismatch
repair gene mutations
Alzheimer’s Autosomal dominant Alzheimer’s disease due to mutations in
disease (a) APP (amyloid precursor protein gene)
(b) PS1 (Presenilin 1 gene)
(c) PS2 (Presenilin 2 gene)
Source: Rose and Lucassen.38 Reproduced by permission from Oxford University Press.
Copyright r 1999.
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exogenous etiology) and (usually) have a multifactorial etiology where
both genes and environmental factors are involved.
When comparing Mendelian with multifactorial disorders, the
former are characterized by a relatively deterministic genotype–phe-
notype relationship, while the latter show a vast complexity resulting
in incomplete penetrance. For example, carriership of the Factor V
Leiden (FVL) mutation increases the risk for venous thromboembo-
lism (VTE) to an estimated 10–20% in a lifetime, but the genotype is
neither sufficient nor necessary for VTE to occur.42
Genetic components of multifactorial traits can affect the suscepti-
bility to disease (clinical/pre-clinical), underlie differences in the
natural history of disease (severity, complications, prognosis), or result
in different therapeutic responses (efficacy, adverse effects).43
Gene–disease associations
Estimates on the frequency of multifactorial diseases indicate that, on
average, more than 46 out of 1000 newborn children in industrialized
countries will manifest such a disease, with a genetic component, by
the age of 25, and 600 individuals (out of 1000) after the age of 25,
which implies a lifetime risk of almost 65%.44 This implies that the
vast majority of people will be affected by one or more complex
diseases. According to many authors, these are presumed to result
from the cumulative effect of mutations of low penetrance at multiple
loci (ie, susceptibility genes) which, if occurring in isolation, would
not have any phenotypic effect. In combination and in the presence of
the necessary environmental influences and/or lifestyle factors, these
mutations increase the risk of disease.45 To identify causal mutations,
variations in the genome have been studied that may be closely linked
to the disease-causing alleles. For a specific individual, heterozygosity
at any given site will in most instance be due to one of the common
single-nucleotide polymorphisms (SNPs),46 defined by a frequency of
both its alleles of more than 1%. Either directly or through linkage
disequilibrium, these variants may contribute significantly to the
genetic risk for common complex diseases. The literature contains
numerous studies of associations between common DNA polymorph-
isms and variation in disease susceptibility, and since 2007 many more
association studies have been published.4,47–49
However, many association studies in the past have been small and
of limited validity. Strong associations found in small studies were
typically not confirmed by larger studies that followed, and it has
become evident that initial association studies tend to overestimate the
genetic predisposition to common diseases.2,36,50
Recently, genome-wide association studies3 and meta-analyses49
have yielded more and more confirmed associations between genetic
variants and common disease. Yet, even the large-scale genome-wide
association study by the Wellcome Trust Case Control Consortium
arrived at the conclusion that the predictive value of known poly-
morphisms will be limited and will therefore be unlikely to trigger
preventive decisions or actions.3
The common disease–common variant hypothesis – proposing that
the genetic risk for common disease is based on a number of
predisposing variants in susceptible populations – appears unlikely
to be correct.29–31,51 However, some argue that it might well be
possible that both common and rare alleles are important.36
The clinical validity of a genetic test is determined by the associa-
tion between the genetic variant to be tested and the disease in
question, measured by sensitivity, specificity, and likelihood ratios,
and the prevalence of the disease, which impacts upon the positive and
negative predictive values.
Recent publications suggest that claims of clinical validity for common
polymorphisms are often premature52–54 because most, if not all,
associations are only of small or modest size (ie, ORo1.4; see Table 3).
Table 3 Findings of recent whole-genome association studies
Disease Source Gene/locus ORhet ORhom P value PAR (%)
Breast cancer Easton et al 55 FGFR2 1.20 1.64 11010 16
Hunter et al 56 FGFR2 1.23 1.63 21076 —
TNRC9 1.23 1.39 11036 —
MAP3K1 1.13 1.27 21020 —
LSP1 1.06 1.17 3109 —
8q24 1.06 1.18 51012 —
Stacey et al 57 2q35 1.11 1.44 51014 14
TNRC9 1.27 1.64 61019 13
Coronary artery disease McPherson et al 58 9p21 1.20 — 4106 13
Myocardial infarction Helgadottir et al 59 9p21 1.25 1.64 11020 21
Obesity Frayling et al 60 FTO 1.32 1.67 31035 20
Diabetes Sladek et al 61 TCF7L2 1.65 2.77 11034 28
SLC30A8 1.18 1.53 6108 24
HHEX 1.19 1.44 3106 19
EXT2 1.25 1.50 1104 16
Steinthorsdottir et al 62 CDKAL1 1.25 1.50 8109 16
Scott et al 63 IGF2BP1 1.14 — 91016 —
CDKN2A/B 1.20 — 81015 —
11p12 1.25 — 4107 —
Zeggini et al 64 KCNJ11 1.14 — 51011 —
PPARG 1.14 — 21014 —
Prostate cancer Yeager et al 65 8q24 1.26 1.58 91013 21
Gudmundsson et al 66 8q24 1.71 — 21014 13
Abbreviations: ORhet, odds ratio – heterozygotes; ORhom, odds ratio – homozygotes; ‘—’, not reported; PAR, population-attributable risk.
Source: Modified from Topol et al.4 Copyright r 2007 American Medical Association. All rights reserved.
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Any precise estimation of disease risks would require numerous
genetic variants to be considered in combination with environmental
factors. As known genetic variants explain only a small proportion of
the estimated heritability of common diseases, current risk estimates
are not stable and the correlation between the predicted and
actual genetic risk is likely to be poor.30 Moreover, not all variants
are known and testable, and knowledge about gene–gene and gene–
environment interactions is often lacking.67 While some authors argue
that discovery of these missing variants may allow useful predictions
of genetic susceptibility to be made in future68, others are more
skeptical.69–73
It should be acknowledged that, in understanding the genetic
susceptibility for many common complex disorders, we are only at
the beginning of finding the pieces of a puzzle of unknown size and
shape. Some people doubt the usefulness of this line of research.74 In
addition, for many disorders, little is known about effective interven-
tions – such as taking medication or altering the lifestyle – to prevent
disease or postpone its onset. In most cases of rare polymorphic
variants, the change in risk would be too small for any public health
intervention to be appropriate. For most diseases, the number of
known susceptibility SNPs would be too small for a polygenic test, but
in some cases a combination of risk variants may confer a sufficiently
high relative risk to support the recommendation of risk-reducing
strategies, such as regular monitoring.75 In public health, more
examples can be given of the use of moderate (non-genetic) risk
factors, such as age, blood pressure, BMI, and waist circumference.
Currently, family history may often be more predictive than genetic
variants, which may only alter disease susceptibility by a factor of 1.2
each, or less. Familial clusters (recognised among close relatives of
affected individuals) may identify subgroups of a population at
increased risk that can form the target for further specialized actions.
Regarding the usefulness of genetic testing or even screening in
common disorders, knowledge of the gene–environment interaction is
argued to be paramount. In case of known gene–environment inter-
actions for certain gene variants, people carrying that variant may
profit the most.76 However, for fixed risk factors, that is, when the
intervention does not change the risk factor itself, the risk–benefit
ratio of an intervention may be lower (or no different) when targeted
at a high-risk group, than for members of the general population.
This means that those who are at highest genetic risk may or may
not be those who gain most from an intervention. It should be noted
that the contribution of genetic factors to some common multi-
factorial diseases are fixed risks and cannot be changed by any
intervention.35
Owing to often greatly reduced penetrance, individuals carrying the
‘high-risk’ form of a gene may not develop the disorder in question,
while individuals without the genetic predisposition may show char-
acteristics of the disease, possibly caused by a single environmental
exposure (eg, smoking, exercise, nutrition).36,77 A precise and com-
prehensive risk assessment is not possible merely on the basis of
genetic variants. If a genetic susceptibility test was used to advise a
subgroup of the population (at high environmental risk) to change
their lifestyle (ie, the environmental risk factor), a proportion of cases
could be avoided. The utility of the test depends on whether or not a
(positive) gene–environment interaction exists. If no interaction
exists, the implementation of a screening program would not auto-
matically improve the population health compared with randomly
selecting the same number of people, and there might even be negative
health benefits because of the screening. For this reason, any assess-
ment of the likely effects on health caused by genetic tests combined
with environmental or lifestyle advice would be greatly facilitated
knowledge of the magnitude (and sign) of any gene–environment
interaction.35,78,79 It can be argued, however, that genetic testing may
be of clinical utility even in the absence of gene–environment inter-
action if taking the test and having knowledge about risk status
supports changes in behavior and life style. As changing habits and
health behavior has proven to be difficult, in some cases genetic testing
might give individuals an extra stimulus. However, currently, research
studying the impact of susceptibility testing on changing behavior is
limited.
Given these provisos, which should not be underestimated, con-
firmed gene–disease associations might perhaps become of importance
for the prediction, prevention, and treatment of common diseases in
the future. Especially the use of genetic susceptibility screening in
asymptomatic individuals would represent a chance for early identi-
fication of individuals at increased risk of a specific condition. This
could lead to reduced morbidity and mortality if interventions are
available to prevent or postpone the onset of disease (see Figure 2).
In the wording of Lango and Weedon,36 ‘y. we finally have the
ability to systematically identify the genetic variants underlying a
range of common disorders from type 2 diabetes to Crohn’s disease,
but when will these findings benefit clinical medicine, and are we on
the right track to using this genetic information to improve clinical
practice? It should be remembered that this type of genetic research is
still in its infancy, and as we have only just acquired the ability,
through GWA studies, to identify a large number of common disease
genes, it is unsurprising that there has been no major impact of this
research on clinical practice as yet. However, the ability of genetic
research to alter treatment and diagnosis, given sufficient time, is
clearly demonstrated by the success in the monogenic field, for
example, in Maturity-Onset Diabetes of the Young (MODY). We
expect there will be a great benefit to clinical medicine in the years to
come, and while prediction of disease and pharmacogenetics
may eventually prove valuable, the greatest clinical benefit of GWA
studies is likely to come from etiological insights into disease
processes.’ However, while most authors recognize that genetic
research can provide insights into disease processes, others are
skeptical about disease prediction. For example, Clayton69 argues
that individual disease prediction is an ambitious aim and that even
if all the relevant genetic variants, including rare variants, were to be
discovered, the combined effect will have modest predictive power for
most diseases.
Healthy
Screening possible
Intervention to avert
disease development
or its consequences
Disease or precursor
detectable
Syptoms develop
Advanced disease
Death
Life prolonged Life prolonged
Desease prevented
Intervention to avert
disease development
Screening possible
SusceptibilityTraditional
Screening pathways
Figure 2 Potential screening pathways.
Source: Reproduced from Goel.80 Copyright r 2001 with permission from
BMJ Publishing Group Ltd.
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Assessment of genetic screening and testing
Elaborate frameworks have been developed for the assessment of genetic
screening programs directed at specific groups or the population at
large, as well as for the assessment of tests used in genetic services. The
evaluation of genetic screening programs has to include evaluation of
the test characteristics, complemented by additional considerations
regarding the screening context (ie, purpose, targeted groups).
Criteria for the evaluation of screening programs. One potential of
genetic testing services for predictive and preventive medicine arises
from the possibility of identifying individuals at risk. In order to target
interventions to individual patients and to improve their health and
prevent disease, the screening of populations or specific subgroups
provides the possibility to determine individual susceptibility to
common multifactorial disorders. Screening is targeted at populations
that are not aware of potentially being at increased risk and have not
sought medical attention for the condition in question. The purpose is
to identify persons at increased risk of a specific disorder (whereupon
further testing can be done, or preventive actions taken) and to offer
follow-up and intervention to benefit the screened individuals. In
1968, Wilson and Jungner developed principles of population screen-
ing that can also be applied in the case of disorders with a genetic
component (see Box 1). Based on the criteria by Wilson and Jungner,22
the Crossroads 99 Group devised a framework to assess susceptibility
testing for breast, ovarian, and colorectal cancer.80 The Crossroads
Criteria are based on a simple model of disease progression (see
Figure 2), which indicates that screening tests primarily detect genetic
susceptibility to disease at a preclinical, asymptomatic phase. The
Wilson and Jungner criteria and the domains of these criteria were
broadened to some extent. For example, the first domain, Knowledge
of disease, was extended to include knowledge of the population; the
criterion of knowledge about the developmental stages of a disorder
was extended so as to include knowledge about risk and susceptibility.
The criterion that a treatment should be available was diverted into
the notion that interventions that have physical, psychological, and
social net benefit should be available. Cost considerations within the
Crossroads Criteria refer to the broader field of societal and health
system issues. Overall, much more attention is paid to ethical, legal,
and social issues. Through these modifications the usefulness of the
original criteria by Wilson and Jungner was confirmed, while, at the
same time, developments in the field of genetic susceptibility testing
were acknowledged.
In 2001, Burke et al81 applied the Wilson and Jungner screening
criteria to genetic testing or screening in three adult-onset conditions
(breast cancer, colorectal cancer, and hemochromatosis). Although the
authors concentrated upon the evaluation of major gene effects, their
work nevertheless confirmed that each of the Wilson and Jungner criteria
can be applied in principle in a genetic testing and screening context.
Table 4 gives a general idea of how the criteria by Wilson and Jungner
can be applied in detail, although it should be noted that some issues
have advanced in recent years (eg, facilities for diagnosis and treatment).
At the same time, Table 4 identifies important knowledge gaps
concerning genetic testing for breast and colorectal cancer, as well as
screening for hemochromatosis. These gaps result from uncertainties
that will be found to be associated with many common diseases. In the
case of breast and ovarian cancer, only a minority of cases are
Box 1 Criteria for assessment of screening
Wilson and Jungner Crossroads 99a
Knowledge of disease Knowledge of population and disease
Condition must be an important problem. Burden of target disease should be important.
Target population or population at risk identifiable.
Recognizable latent or early symptomatic stage. Considerable level of risk or latent or preclinical phase.
Natural course of condition (including development from latent to
declared disease) should be adequately understood.
Natural course (from susceptibility to precursor, early disease, and advanced disease)
should be adequately understood.
Knowledge of test Feasibility of screening procedures
Suitable test or examination. Suitable test or examination.
Test acceptable to the population. Entire screening procedure acceptable to the population.
Case finding should be a continuing process and not
‘once and for all’ project.
Screening should be a continuing process and should encompass all elements of
screening procedures.
Treatment for disease Interventions and follow-up
Accepted treatment for patients with recognized disease. Interventions that have physical, psychological, and social net benefit available.
Facilities for diagnosis and treatment available. Facilities for adequate surveillance, prevention, treatment, education, counselling,
and social support available.
Agreed on policy concerning whom to treat as patients. Consensus on accepted management for those with positive test results.
Cost considerations Societal and health system issues
Costs of case finding (including diagnosis and treatment of
patients diagnosed) economically balanced in relation to possible
expenditures on medical care as a whole.
Costs should be balanced in economic, psychological, social, and medical
terms and with health-care expenditures as a whole.
Appropriate screening services accessible to the entire population, without adverse
consequences for non-participants.
Appropriate confidentiality procedures and antidiscrimination provisions
for participants and non-participants.
aEthical, legal, and sociobehavioral issues are considered across all domains. Screening should be considered within a framework that recognizes fundamental human rights.
Source: Reproduced from Goel.80 Copyright r 2001 with permission from BMJ Publishing Group Ltd.
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accounted for by mutations in the highly penetrant genes, and only
these can currently be screened for. The rest of the genetic ‘load’ of
both disorders is likely due to a combination of the effects of multiple
minor genes interacting with environmental influences.
Regarding the relevance of population screening for genetic sus-
ceptibility, Khoury et al82 suggested some modifications and refine-
ments to the Wilson and Jungner criteria on the basis of the
Crossroads modifications.
The criteria for the evaluation of screening programs provide a
framework to assess the benefit of genetic screening by considering
different dimensions of a screening program before its widespread
implementation (see Boxes 1 and 2). The quality of a test is the most
relevant aspect when it comes to its application in a screening program.
Before a final decision is made as to whether or not to implement a
genetic screening program, the relevant genetic tests have to be
evaluated according to their overall performance and effectiveness.
Although the often revised and refined Wilson and Jungner criteria
are still frequently referred to, more elaborate frameworks have been
developed in recent years that take elements of the setting in which a
genetic test is used into consideration (for instance, in a screening
program) and combine this with quantitative information about the
disorder and the tests to be applied. The ACCE framework is an
example of such a framework, quantifying as many criteria as possible
(eg, public health burden, quality of a test) and thereby facilitating a
Table 4 Application of screening principles to genetic screening
BRCA1/2 mutations APC 11307K mutation HFE mutations
Testing women with family histories
indicating X10% chance of mutation Testing people of Ashkenazi descent General population screening
Important health problem Yes (breast and ovarian cancer) Yes (colorectal cancer) Yes (iron overload disease)
Accepted and specific treatment Effectiveness of interventions to reduce
risk uncertain; prophylactic surgery
unacceptable to many women
Reduced cancer mortality with colorec-
tal screening, but need for genotypic-
specific screening program uncertain
Yes (phlebotomy)
Facilities for diagnosis and treatment Adequacy of testing, counselling, and
follow-up, not evaluated in clinical
or public health settings
Adequacy of testing, counselling, and
follow-up, not evaluated in clinical or
public health settings
Adequacy of testing, counselling, and
follow-up, not evaluated in clinical or
public health settings
Early stage known Yes Yes Yes
Suitable test Uncertain predictive value Uncertain predictive value Uncertain predictive value
Test is acceptable Uncertainty concerning the health
benefit from screening; social and
psychological risks not known
Uncertainty concerning the health
benefit from screening; social and
psychological risks not known
Uncertainty concerning the health ben-
efit from screening; social and psycho-
logical risks not known
Natural history known No Probably not different from sporadic
colorectal cancer
No
Agreement about when to treat No No No
Cost of care, funding acceptable Uncertain Uncertain Uncertain
Ongoing process Cannot yet be addressed Cannot yet be addressed Cannot yet be addressed
Source: Reproduced with permisson from Burke et al.81 The publisher for this copyrighted material is Mary Ann Liebert, Inc. publishers.
Box 2 Principles of population screening as applied to genetic susceptibility to disease
Public health assessment
The disease or condition should be an important public health burden to the target population in terms of illness, disability, and death.
The prevalence of the genetic trait in the target population and the burden of disease attributable to it should be known.
The natural history of the condition, from susceptibility to latent disease to overt disease, should be adequately understood.
Evaluation of tests and interventions
Data should be available on the positive and negative predictive values of the test with respect to a disease or condition in the target population.
The safety and effectiveness of the test and accompanying interventions should be established.
Policy development and screening implementation
Consensus regarding the appropriateness of screening and interventions for people with positive and negative test results should be based on scientific evidence.
Screening should be acceptable to the target population.
Facilities should be available for adequate surveillance, prevention, treatment, education, counselling, and social support.
Screening should be a continual process, including pilot programs, evaluation of laboratory quality and health services, evaluation of the effect of screening, and
provisions for changes on the basis of new evidence.
The cost effectiveness of screening should be established.
Screening and interventions should be accessible to the target population.
There should be safeguards to ensure that informed consent is obtained and the privacy of those tested is respected, that there is no coercion or manipulation, and that
those tested are protected against stigmatization and discrimination.
Source: Khoury et al.82 Copyright r 2003 Massachusetts Medical Society. All rights reserved.
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more detailed and rational assessment of the potential benefits of
testing or screening.83
The ACCE framework was developed by the Centers for Disease
Control and Prevention (CDC, USA), National Office of Public Health
and the Foundation of Blood Research. It has been proposed for the
assessment of emerging new genetic tests.84 The CDC initiated another
project, the Evaluation of Genomic Applications in Practice and
Prevention (EGAPP), in order to support the development of a
systematic process for evaluating genetic tests and other genomic
applications that are in transition from research to clinical and public
health practice.85 So far, the EGAPP has provided evidence reports on
several genetic tests (eg, for ovarian cancer, cytochrome 450 poly-
morphisms, hereditary non-polyposis colorectal cancer, and gene
expression profiling tests in case of breast cancer).
Similar approaches have been taken in Canada, the United King-
dom, and Germany, where evaluation processes have started. The
United Kingdom Genetic Testing Network Steering Group, which is
involved in the commissioning and provision of genetic tests in the
UK National Health Service (NHS), has endorsed and adapted the
ACCE core principles to produce a ‘gene dossier’ for more than 150
genetic tests,86 most of which are for clinical use.87 In Canada,
CanGe`neTest aims to evaluate the effectiveness of genetic laboratory
services in Canada and to develop tools and approaches to help
decision makers to establish the relevance of new diagnostic genetic
technologies.88 The German Society of Human Genetics is currently
publishing a series of disease-specific ‘indication criteria for genetic
testing’.89 This activity is based on a preceding Eurogentest work-
package and is now being complemented by the Eurogentest ‘clinical
utility gene cards’.90
Quantitative measures and the ACCE framework. When evaluating
genetic tests, many uncertainties will arise. The genetic epidemiology
of the condition under consideration has to be considered within the
scope of any evaluation. By ‘genetic epidemiology’ we mean ‘the study
of genes and disease in populations, the design of epidemiological
studies, and assessment of the impact of random variation, bias and
confounding on their results’.41 Essential components of an assessment
include the burden of suffering from a potentially increased disease
risk, epidemiological measures (such as the frequency of disease-
causing mutations in genes in different subgroups, and the contribu-
tion of genetic factors to the prevalence of disorders in populations),
the accuracy of the test, and the comparison with alternative methods
of detection.
Epidemiology deals first of all with measuring the effects of
exposures (eg, family history of disease, lifestyle factors) upon disease
risk. The primary goals are to obtain valid measures for the frequency
of disease and exposures, as well as measures of association between
the exposure and the causal effect.
In order to evaluate the assessment of tests and screening programs
in quantitative terms, several measures have been developed and used
by different authors (Box 3):
We will focus on one approach for the evaluation of outcomes of
genetic testing that integrates quantitative measures: the ACCE
model92 (see also Burke and Zimmern93).
It is relevant to notice that the reviews performed under ACCE or
EGAPP, as far as common disorders are concerned, focused on the
monogenic subforms. If a test for low-risk alleles is to be assessed via
the model, many issues in the model, as discussed below, currently,
probably, cannot be properly addressed.
The array of studies leading to the development of the ACCE model
dealt with the evaluation of test performance, quality control, and
effectiveness. For that purpose, tests for several disorders (CF, hemo-
chromatosis, VTE, breast and ovarian cancer, colorectal cancer) have
been assessed regarding the components that later became the core
elements of the ACCE model. It is a model process for the evaluation
of information on emerging genetic tests, including the collection,
evaluation, interpretation, and reporting of data about DNA and
related testing services for genetically predisposed disorders. The main
objective is to provide policy makers with up-to-date and reliable
information for decision making.
The four eponymous components of the ACCE model (Analytic
validity–Clinical validity–Clinical utility–Ethical, legal, and social
implications) as well as their elements and relations to each other
are displayed in the ACCE wheel (Figure 3). At the hub of the ACCE
wheel are the clinical disorders and the setting in which testing is done.
The evaluation process begins only after the clinical disorder and
setting have been clearly established.
Specific questions 1–7 (see Appendix A) help to define the disorder,
the setting, and the type of testing.
The CDC website92 explains the components analytic validity,
clinical validity, clinical utility, and ethical, legal and social implica-
tions as follows:
‘The analytic validity of a genetic test defines its ability to
accurately and reliably measure the genotype of interest. This aspect
of evaluation focuses on the laboratory component. The four specific
elements of analytic validity include analytic sensitivity (or the analytic
detection rate), analytic specificity, laboratory quality control, and
assay robustness. Analytic sensitivity defines how effectively the test
identifies specific mutations that are present in a sample. Analytic
specificity defines how effectively the test correctly classifies samples
that do not have specific mutations (although the term ‘mutation’ is
used here, the terms ‘polymorphism’ or ‘variant’ may be more
appropriate for certain situations). Quality control assesses the pro-
cedures for ensuring that results fall within specified limits. Robustness
measures how resistant the assay is to changes in pre-analytic and
analytic variables.’ Specific questions 8–17 (see Appendix A) organize
the information available to document analytic validity.
Figure 3 ACCE evaluation process for genetic testing.
Source: Centers for Disease Control and Prevention (CDC).92
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‘The clinical validity of a genetic test defines its ability to detect or
predict the associated disorder (phenotype). The four elements of
analytic validity are all relevant to assessing clinical validity, along with
six additional elements: clinical sensitivity (or the clinical detection
rate), clinical specificity, prevalence of the specific disorder, positive
and negative predictive values, penetrance, and modifiers (gene or
environmental). Penetrance defines the relation between genotype and
phenotype and allows the frequency of the clinical expression of a
genotype (expressivity) to be determined. Clinical sensitivity measures
the proportion of individuals who have a well-defined clinical disorder
(or who will get the disorder in the future) and whose test values are
positive. Clinical specificity measures the proportion of individuals
who do not have the well-defined clinical disorder and whose test
results are negative. Prevalence measures the proportion of individuals
in the selected setting who have, or who will develop, the phenotype.
The positive and negative predictive values more meaningfully define
the genetic test performance by taking into account clinical sensitivity,
clinical specificity and prevalence.’ Specific questions 18–25 (see
Appendix A) help organize the information available to document
clinical validity.
‘The clinical utility of a genetic test defines the elements that need
to be considered when evaluating the risks and benefits associated with
its introduction into routine practice. The natural history of the
specific disorder needs to be understood so that such considerations
as optimal age for testing might be taken into account. Another factor
to be considered is the availability and effectiveness of interventions
aimed at avoiding adverse clinical consequences (if no interventions
are available, for example, testing may not be warranted). Quality
assurance assesses procedures in place for controlling pre-analytic,
analytic, and post-analytic factors that could influence the risks and
benefits of testing. Pilot trials assess the performance of testing under
real-world conditions. Health risks define adverse consequences of
testing or interventions in individuals with either positive or negative
test results. Economic evaluation helps define financial costs and
benefits of testing. Facilities assess the capacity of existing resources
to manage all aspects of the service. Education assesses the quality and
availability of informational materials and expertise for all aspects of a
screening service. Monitoring and evaluation assess a program’s ability
to maintain surveillance over its activities and make adjustments.’
Specific questions 26–41 (see Appendix A) help organize the informa-
tion available to document clinical utility.
‘Ethical, legal, and social implications surrounding a genetic test
are represented y by a penetrating pie slice, implying that the
safeguards and impediments should be considered in the context of
Box 3 Quantitative measures
Penetrance of a genetic variant
Probability that traits or characteristics associated with that variant will manifest (within a specified period of time)
Incidence
Number of new cases of disease occurring in a population (within a specified period of time)
Prevalence
Proportion of affected individuals in a population (at a given moment of time)¼incidence rateaverage duration of disease
Sensitivity or detection rate (DR)
Proportion of affected individuals (or those who become affected within a specified period of time) with a positive (unfavorable) screening test result
Specificity
Proportion of unaffected individuals with a negative screening test result
False-positive rate
Proportion of unaffected individuals with a positive screening test result¼1specificity
DR5
Detection rate for a 5% false-positive rate
Positive predictive value (PPV)
Risk of disease among individuals with risk factor (with positive screening test result) (clinical impact)
Population attributable fraction (PAF)
Proportion of cases that could be prevented if the risk factor was absent (the public health impact)
ROQ15
Relative odds of the highest fifth of the risk factor distribution compared with people in the lowest fifth
Number needed to treat (NNT)
Number of people needed to treat for one success
Number needed to screen (NNS)
Number of individuals needed to screen to prevent one case of disease (measure to assess the performance of screening, combining penetrance and frequency with
reduction in risk of disease)¼inverse of the frequency divided by the penetrance divided by the reduction in risk of disease¼(1/FpRR)
Source: Based on Stewart et al,41 Wald et al,91 Khoury and Wagener,78 Vineis et al.77
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the other components.’ Specific questions 42–44 (see Appendix A)
help organize the information available to document ELSI issues.
GENETIC TESTING AND SCREENING IN COMMON DISORDERS
Forms of screening
In many European countries, population screening is best known to
the general public from the examples of breast cancer screening by
mammography and PAP smears for cervical cancer screening. A
defined segment of the population (women in a certain age group)
is invited at a specified time interval.
Genetic screening programs exist in most European countries at
least in the antenatal and neonatal phases of life. In this type of
program, all pregnant women are invited for determination of their
rhesus blood group, and assessment of risk of Down’s syndrome (eg,
by maternal serum screening) or neural tube defect (eg, by ultrasound
screening). All newborns can participate in the programs using a
blood test to diagnose treatable conditions as early as possible in order
to avoid irreversible damage. Most newborn screening programs start
with PKU. When adhering strictly to a special diet, affected infants will
not develop severe mental retardation.
In some countries genetic screening programs exist that are aimed
at high-risk subpopulations. Ethnicity or ancestry may be used to
identify high-risk groups. In Finland for instance, indigenous Finnish
newborns do not need screening for PKU because the disease risk in
Finnish people is close to zero, while ‘migrants’ from other European
countries have a higher risk. In southern European countries, such as
Greece and Italy, screening programs for hemoglobinopathies, such as
b-thalassemia, have been implemented decades ago.94
The genetic screening programs mentioned above either aim to
provide people with information that enables them to make informed
reproductive decisions (antenatal screening for Down’s syndrome or
neural tube defects) or relate to treatment or prevention options (anti-
D for rhesus-negative mothers who gave birth to a rhesus-positive
child to prevent rhesus antagonism in the next pregnancy; diet for
PKU for secondary prevention). These two different aims of screening
programs need to be separated in discussions of societal implications.
Family structure is sometimes used to approach family members at
high risk. This is referred to as cascade screening: first- or second-
degree family members of FH patients are systematically invited to
have a test as well. Similar approaches exist for hereditary tumors.
In the age of genomics, screening in common disorders might be
relevant later in life for screening for conditions where treatment or
prevention is possible. People at high risk of developing a common
disorder might benefit from personalized prevention programs to
reduce their risk or postpone the onset of disease. Probably the
number of applications that relate to informed reproductive decisions
will be rather small.
Testing and screening strategies
One or several variants for one disease. Some genetic association
studies report high relative risks for a specific genetic variant and
conclude that ‘genetic testing might become a future approach to
identify individuals at risk’.95 However, it remains unclear whether
such genetic risk classifications have sufficient predictive value to be
useful.69–73 Critical analyses of this kind of statement often reveal that
the clinical validity of a test, focussing on one gene, let alone one allele
only, is rather limited.4,96–98 Nevertheless, for diabetes, for instance,
several susceptibility genes have been identified; yet, a singleton gene
marker (TCF7L2 diabetes SNP essay) has been marketed for $500.4
Individuals who pay to have such a marker analyzed are only getting
an ‘ice-pick’ genome view of susceptibility: other risk genes, modifier
genes, protective alleles, as well as lifestyle factors are not being taken
into account. At least the use of information on several genetic
variants at a time (genetic profiling) would in most cases be more
efficient, particularly if there is no gene–gene interaction. In this case,
however, the distribution of log-odds ratios will be close to a normal
distribution, with many people at close to average risk and very few at
markedly higher or lower risk. As the variance of this distribution
increases when more and more markers are included, an increasing
number of people will have either a low or a high risk.98
One or several diseases. While genetic variants may indicate an
increased risk for one disease, they may be associated with a decreased
risk for others. Preventive and therapeutic interventions aimed at
eliminating the negative effects of a single genetic variant for one
disease may increase the risk of another disease.6,98
Some authors combine the state of knowledge regarding the
genetics of several disorders and endorse a more global approach,
for instance to cardiovascular risk.5
Historically, cardiovascular risk factors such as hypertension, BMI,
age, smoking, fasting glucose level, salt intake, etc, have been used in
primary care and public health (including occupational health) to
tailor prevention programs to individual risk profiles. It has been
claimed that public health professionals will increasingly have to
incorporate genetic knowledge into their evaluation, at the population
level, of the risk for CVDs.5 A list of specific recommendations to
translate research findings into effective genetic screening programs
would include the development of multidisciplinary collaborative
research teams, the evaluation of how behavioral and environmental
factors interact with genetic variants to influence CVD risk, to prepare
proactively for effective genetic screening programs, and to educate
researchers, clinicians, public health professionals and the general
public.5
Other authors do recognize the shift from understanding the
biological processes to the complex biology of hemostasis, thrombosis,
inflammation, endothelial dysfunction, and plaque instability. How-
ever, they propose to include only a limited number of novel
biomarkers in preventive health care because data are scant.99
Testing and screening for common disorders in Europe
In the research for several disorders, associations between genetic
variants and disease risk of potential clinical relevance have been
established, for instance for hereditary breast and ovarian cancer,
colon cancer, diabetes mellitus (MODY subtypes), thrombosis, cardi-
ovascular disorders, celiac disease, and Alzheimer’s disease. Although
these examples again relate to monogenic subforms of common
disease, they can nevertheless be used to reflect on what is possible
or might be expected, and what might be perceived as major obstacles
in using the new genetics in public health. Testing for these monogenic
subtypes is being implemented in health care in some countries. A
major criterion to decide what is or is not implemented in health care
is clinical utility. For these examples, tests have a high or intermediate
predictive value, and preventive interventions are available. It has to be
borne in mind that screening for low-risk alleles in common disorders
would raise some similar, but also some rather different issues because
of the (much) lower predictive value, difficulties in establishing the
utility of interventions, the setting of the test (commercial or health
care), and ways of informing patients and the public (see also the
section ‘Genetic testing and screening in common disorders: what can
we learn from HH and FH?’).
The presence of a germline BRCA1 or BRCA2 mutation may cause
hereditary breast and ovarian cancer, which has consequences for
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treatment and prevention both in patients and in healthy family
members. If a young woman is diagnosed with breast cancer, and is
found to have a BRCA1/2 mutation, surgery might not be limited to
removing the tumor alone. Prophylactic surgery (mastectomy, sal-
pingo-oophorectomy) may be considered to reduce the risk of future
breast and ovarian cancer. Family members may also wish to consider
genetic testing. For healthy family members carrying the mutation,
screening would start earlier, MRI can be offered, and prophylactic
surgery can be considered.
Not only germline mutations may be of clinical relevance, but also
gene expression may be relevant for health care, especially in cancer. In
breast cancer treatment, response to Herceptin (trastuzumab) therapy
can be determined using HER2 (ERBB2) testing of tumor tissue.100 In a
more experimental setting, the expression of 70 genes appears to be a
strong predictor of prognosis.101 The so-called Mammaprints is a gene
expression profiling test on tumors that helps discern who might profit
from chemotherapy and who might not.102 BRCA1 and BRCA2 testing
for inherited predisposition, as well as HER2 testing for therapy fit well
within the existing practices of gynecologists and oncologists and have
been implemented in regular health care. Clinical geneticists have
mainly been involved in genetic counselling and developing guidelines
for the high-risk groups of BRCA1 and BRCA2 mutation carriers.
Increasingly, molecular and immunohistochemical parameters are
being included in the delineation of tumor subtypes in order to
predict the response to therapy. Examples are determining micro-
satellite instability (MSI) and immunohistochemistry in colorectal
cancer, which can indicate a reduced response to certain chemother-
apeutic agents – but could also indicate an increased chance of Lynch’s
syndrome – and parameters of breast cancers such as basal phenotype,
medullary histology, and ‘triple-negative’ receptor status (negativity
for estrogen and progesterone receptor and the tumor marker HER-2/
neu), which could indicate an increased chance that the patient is a
BRCA1 mutation carrier. Clearly, these tests are clinically useful in that
they can alter patient management, but they may also indicate the
presence of a strongly cancer-predisposing condition (Lynch’s syn-
drome or BRCA1 mutation, respectively). Further evaluation with
expression arrays will in the future delineate more subtypes of cancers,
which may behave in different ways. These parameters may also reveal
an increased chance that an individual may be a carrier of a germline
mutation in a cancer susceptibility gene. Such tests therefore should
only be done in connection with counselling regarding the possible
implications and the need for further genetic tests should the test
result be ‘high risk’.
Regarding breast cancer, at present, much research is aimed at
finding susceptibility genes of moderate and low penetrance in the
wider population. Most of these polymorphisms alone have minimal
effects upon risk, but when it becomes possible to test a combination
of those genetic variants, this may result in the detection of profiles
associated with a significant increase in risk of developing breast
cancer. Only then could it be considered as a screening test for women
to assess their relative risk. Currently, combining all the common
genetic variants associated with breast cancer does not improve risk
predictions compared with existing models using non-genetic risk
factors.103 Pharoah et al104 argue that, currently, a test based on the
known, common moderate-risk alleles does not provide sufficient
discrimination to warrant individualized prevention (see also Ripper-
ger105). However, a screening test might in the future become relevant
in the context of a population screening program. Thus, for instance,
it could be used to identify higher-risk women who might be offered
mammographic screening from an earlier age than the standard for
population screening (from 48 or 50 years of age). Pharoah et al104
stress that, at present, many issues such as evidence, efficiency and
acceptability of such a screening program still need to be established.
For instance, MRI screening would be too costly unless targeted at
patients at high risk.
The panel of susceptibility genes might differ between popula-
tions.105 For example, in Poland, a panel of markers has been
established that might account for 92% of breast cancers in the Polish
population,106 which could render screening in that particular popu-
lation feasible.
Hereditary non-polyposis colon cancer (HNPCC) is known to be
caused by germline mutations in several genes (MLH1, MSH2, MSH6,
and PMS2). As with breast cancer, the presence of (highly penetrant)
mutations may modify the therapeutic approaches taken both for
patients and for their relatives. Family members can be tested for the
specific mutation found in their affected relative. In an ACCE review it
was mentioned that the Cancer Genetic Studies Consortium recom-
mends monitoring of carriers of most notably the MLH1, MSH2, and
MSH6 mutations using colonoscopy at 1–3-year intervals coupled
with transvaginal ultrasound or endometrial aspiration annually for
women, because women may develop endometrial and ovarian
malignancies.107 When the mutation is absent, the risk of developing
cancer is reduced to the population risk. The ACCE review suggests
that because of the cost of DNA sequencing coupled with the low
frequency of HNPCC mutations among individuals with colorectal
cancer, testing all cases of newly diagnosed cases of colorectal cancer
would not be indicated. Instead, a high-risk subgroup could be
selected by using family history and/or MSI testing of the tumor.
Drawbacks of this procedure would be a loss of cases, as only about
86% of individuals with HNPCC-associated cancer will have a positive
family history, and about 90% of colorectal cancers caused by HNPCC
mutations will display MSI.107
Similarly, in cardiac disorders, a distinction can be made between
monogenic subforms, such as cardiomyopathies and primary arrhyth-
mias, and multifactorial disease etiologies.108,5 Identifying risk carriers
enables preventive and symptomatic treatment with medications as
well as devices (implantable cardiac defibrillator (ICD), which may
prevent sudden cardiac death (SCD) at a young age. Hypertrophic
cardiomyopathy (HCM) is the most common autosomal dominant
heart disease (with a prevalence of at least 1 in 500) and is the main
cause of SCD while on the playing field. On the other hand, most
HCM patients have a normal life expectancy. The causal mutation can
currently be detected in approximately half of the index patients,
facilitating cascade screening. In carriers, regular cardiac screening is
possible, aimed at well-known risk factors for SCD (such as non-
sustained ventricular tachycardias, massive hypertrophy, and a family
history of SCD). The yearly risk of SCD in manifest HCM patients is
1%, which might rise to 5% in those with two or more risk factors.
Idiopathic dilated cardiomyopathy (DCM) is familial in about 30% of
cases and is genetically very heterogeneous, making DNA testing
difficult. Active cardiac screening and follow-up of first-degree rela-
tives of DCM patients is advised, however, because early treatment is
expected to improve the clinical course. Arrhythmogenic right ven-
tricular cardiomyopathy (ARVC) is also known as a frequent cause of
SCD during competitive sports, in males in particular. The clinical
hallmarks of this disease are the replacement of the muscle of the right
(and sometimes also left) ventricle by fat and connective tissue, with
dilatation of the ventricle(s) and severe arrhythmias. The genetics of
ARVC are very complicated, with several mutations detected in more
than one ARVC gene in many patients, complicating cascade screen-
ing. Cardiologic screening (including MRI) is advised for all first-
degree relatives of ARVC patients. The only effective (preventive)
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therapy is an ICD. The long QT syndrome is the best-known example
of a primary arrhythmia syndrome. The prevalence is 1 in 2000. The
molecular cause can be detected in up to 70% of the index patients.
Treatment is mostly possible with beta-blockers in the two most
prevalent forms of the long QT syndrome (caused by mutations in
the KCNQ1 and KCNH2 genes). On the other hand, in the long QT
syndrome caused by mutations in the SCN5A gene (15% of cases),
beta-blockers may be harmful and ICD should be considered. Also,
avoidance of certain drugs (ion-channel-blocking agents) that may
prolong the QTc interval is useful to prevent arrhythmic events.
Formerly healthy people using these substances sometimes get severely
prolonged QT intervals and life-threatening arrhythmias, called the
acquired long QT syndrome. In some of these patients, mutations of
variants in the known long QT genes are detected.
In cardiogenetic outpatient clinics, cardiologists cooperate with
(clinical) geneticists and genetic counsellors to systematically identify
people at risk for SCD due to genetic factors. In the general popula-
tion, family history of SCD at a young age in conjunction with
phenotypic information could be used to detect patients at risk and
establish whether the etiology is Mendelian or multifactorial. If a
person under the age of 40 dies suddenly and unexpectedly and no
cause can be detected, a genetic heart disease can be diagnosed in up
to 40% of the families by cardiac screening of first-degree relatives.109
In presumed multifactorial disease, myocardial infarction with pri-
mary ventricular fibrillation for instance, a positive family history of
SCD is found more often than in patients with myocardial infarction
without VF, suggesting one or more underlying genetic factors.110 If
possible, prevention can be targeted at the underlying risk factors.108,5
For diabetes mellitus, genetic testing may also modify or specify
diagnosis and prognosis. MODY subtypes have an autosomal domi-
nant pattern of inheritance. Recurrence risk is thus higher than in
other types of diabetes. Furthermore, MODY subtypes tend to start at
an early age but may have different clinical implications. MODY2 due
to glucokinase mutations is often mild. The prevalence of micro-
vascular complications is lower than in late-onset type 2 diabetes. The
hyperglycemia is usually responsive to diet. MODY3 due to HNF1A
mutations is a more severe form of diabetes. These patients are more
sensitive to the hypoglycemic effect of (oral) sulfonylureas. Thus,
insulin treatment may be postponed. MODY subtypes 2 and 3
together account for the majority of MODY cases. The rare subtype
MODY5 due to HNF-1b mutations is associated with a rapid reduc-
tion in b-cell mass and requires rapid insulin treatment. This high-
lights the importance of recognizing subtypes to optimize their clinical
approach.111
For type 2 diabetes mellitus, in 2009, SNPs in 24 different genetic
loci had been identified.112 Most of these genetic loci are found to be
associated with the insulin secretion pathway rather than insulin
resistance. However, these loci do not seem to offer greater predictive
value in determining diabetes risk than do commonly used pheno-
typic risk factors and family history.112
For celiac disease, the relevance of genetic testing (HLA-DQ2 and
DQ8 subtypes) for prevention is debated in the broader context of the
pros and cons of early diagnosis through screening.113 Celiac disease is
an important health problem for the individual and the community
because of its high prevalence, associated specific and non-specific
morbidity, and long-term complications, of which the most important
are gut malignancy and osteoporosis.113 The vast majority of cases
remain undiagnosed. The prophylactic benefits of early diagnosis
through screening for individuals with mild enteropathy may be
low, and there is no consensus on whether or not to treat individuals
with mild symptoms.
Alzheimer’s disease is known to be associated with variation in the
apolipoprotein E gene (APOE). The therapeutic response in AD is
genotype-specific, with APOE*4/4 carriers representing the worst
responders to conventional treatments,114 such as donepezil, rivastig-
mine, galantamine, and memantine. This treatment aims to slow
down the disease process115 and is administered in some countries,
most notably the United States. Furthermore, the association of the
APOE-4 allele with specific genetic variants of other genes (eg,
CYP2D6, angiotensin-converting enzyme (ACE)) negatively modu-
lates the therapeutic response to multifactorial treatments affecting
cognition, mood, and behavior.114 Pharmacogenomic testing could
thus help to individualize treatment in patients already showing
symptoms of AD. This application should be distinguished from
susceptibility testing for AD in the general population. The risk of
developing AD for APOE*4/4 carriers is higher compared with non-
carriers; yet, more than half of the carriers will not develop AD. As
there are no effective ways to prevent or cure Alzheimer’s disease,
population screening is not desirable.
In behavioral and neuropsychiatric disorders, associations between
gene variation and behavior have been shown to be extremely difficult
to establish. Especially in this area, social and ethical issues regarding
stigma and identity are further major obstacles for genetic testing.
Venous thrombosis is caused by a combination of genetic and
environmental factors. Although different mutations influence coagu-
lation, FVL is the most common genetic risk factor for venous
thrombosis. About 5% of the white population carries this mutation.
Currently, the test for this mutation is one of the world’s most heavily
used genetic tests.
It has been debated whether testing for FVL might be relevant in
specific situations such as before surgery, during pregnancy and
childbirth, and before prescribing oral contraceptives.116 When a
patient already has an established venous thrombosis, testing might
be relevant, as recurrence risk is higher in carriers. However, the risk of
developing venous thrombosis is still low and should be weighed
against the consequences for the use of contraceptives and unwanted
pregnancies. Cohn et al117 suggest that testing should be performed
with restraint because there are no benefits and no direct consequences
in terms of treatment. A US Department of Health & Human Services
technology assessment on testing for FVL and prothrombin G20210A
concluded:118 ‘There is no direct evidence that testing for these
mutations leads to improved clinical outcomes in adults with a history
of VTE or their adult family members. The literature supports the
conclusion that while these assays have high analytic validity, the test
results have variable clinical validity for predicting VTE in these
populations and have only weak clinical utility’ (see also Segal et al119).
These examples of the potential use of predictive and susceptibility
testing and screening for common disease show the relevance for three
domains: diagnosis and prognosis, individualized treatment and
disease management, and disease prevention. For these three domains,
genetic information could be used in current practices, or in other
cases, new organizations or services might need to be established.
Besides, for all the three domains, the role of clinical geneticists in
educating other health-care professionals or in helping reorganize
health care merits discussion. As the examples show, it can be
necessary to select a high-risk group in which further testing or
monitoring is indicated, as in some arrythmias. In some other
instances, the role of geneticists may be to discuss the limited clinical
relevance and thus avoid implementation in health care. However, the
criteria for selecting and the cases lost by selecting may pose still
further problems that need to be addressed when contemplating
balancing the pros and cons of introducing genetic testing or screening
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in a particular health-care setting. Furthermore, it should be noted
that, for most common disorders for which genetic factors are
being identified, susceptibility testing for low-risk alleles, let alone
susceptibility screening, is currently not indicated for reasons of
clinical validity and utility, as explained in the section ‘Gene–disease
associations’.
Genetic testing and screening in common disorders: what
can we learn from HH and FH?
FH is considered to be a monogenic condition, but there might be
relevant lessons for screening in common disorders. FH is a highly
penetrant autosomal dominant disorder caused by a mutation in the
low-density lipoprotein receptor gene. Prevalence is estimated to be 1
in 500 in Western countries. Cardiovascular problems can be already
present in early adulthood, and preventive medication (statins) can be
offered to reduce the risk. In several countries, family or cascade
screening has been introduced for FH.120 There may be an analogy
with some common chronic disorders, such as diabetes, where it is
becoming increasingly clear that having a family member with a
certain disorder can be an important risk factor in developing a
disorder.121 Thus, forms of cascade screening or collecting data on
family history in FH might be explored to see what aspects might be
relevant for genetic screening in common disorders.
In the Netherlands, since 1994 a genetic screening program for FH
has been organized as a cascade screening, which has been upscaled to
the world’s first national genetic screening program for FH in 2004.122
The contacting and testing of family members is organized via an
intermediary organization that could act as an example for organizing
cascade screening: the Foundation for Tracing Familial Hypercholes-
terolaemia (StOEH) that functions as a registry. After an index patient
has been found and diagnosed, StOEH organizes the contacts with the
family members and collects blood samples for testing. This solves
several issues of time management, central data gathering, quality
control, and informing patients and relatives. Genetic field workers
have an important role in informing patients and family and making
family screening possible.
The relation with primary care is a key issue: StOEH can perform
effectively only when a sufficient number of index patients are found.
Whereas also hereditary hemochromatosis (HH) can be considered
to be a monogenic disorder, because of the low-to-moderate pene-
trance of the associated variant, screening using the genetic test would
resemble screening for risk status as in screening for multifactorial or
common complex disorders, such as diabetes. Therefore, experiences
with and discussions about HH screening could provide insights when
reflecting on screening for those common disorders for which new
tests might be developed in the future.
The mutations underlying HH are among the most common
autosomal recessive mutations in people of Northern European origin.
Hemochromatosis is characterized by iron overload in tissues and
organs of male patients usually over 40 years, and in female patients
after menopause. Currently many patients are detected only after
severe organ or tissue damage has occurred.
Several tests are available for measuring iron levels in serum.123 A
DNA-based genetic test became possible when in 1996 the C282Y and
H63D mutations were discovered in the HFE gene. In people from
Northern European origin, about 85% of people clinically diagnosed
with hemochromatosis are homozygous for the C282Y mutation.
About 1 in 200 of this population is homozygous for the C282Y
mutation.124 In Italy, homozygosity occurs less frequently than in
Portugal and Northern European countries, whereas in Northern
Ireland homozygosity is estimated to be around 1 in 100.125
Arguments in favor of implementing population genetic screening
for HH are the fact that a diagnostic test and a treatment are available
and that timely intervention (phlebotomy or blood-letting to remove
excess iron) can prevent morbidity. Yet, at the 1997 US Centers of
Disease Control and the National Human Genome Research Institute
Consensus Meeting125,126 it was stated that screening was not recom-
mended, as there were several issues that needed to be resolved first.
Knowledge of the penetrance of the disorder was lacking, as well as
evidence on the optimal time of screening, treatment, and psycholo-
gical consequences of screening. Not all homozygotes develop iron
overload, and not all patients with iron overload develop organ and
tissue damage.127 Debate on the clinical expression is still going on. In
2002 Beutler et al128 argued that penetrance is actually quite low and
they estimated that less than 1% of homozygotes would develop full-
blown clinical hemochromatosis. This would result in less favorable
calculations for cost effectiveness. However, in 2008, Allen et al129
reported, for Australia, iron-overload-related disease in more than
28% of male C282Y homozygotes. This confirms earlier findings from
a German pilot study aimed at insurants of a German sickness fund, in
which 8 out of 34 newly diagnosed homozygous C282Y mutation
carriers were found to show iron accumulation with further signs or
symptoms of HH.130,131
Screening of first-degree family members, most notably siblings, of
affected individuals has been suggested and has been implemented in
many countries. Siblings have a 25% chance of having the same
predisposing genotype and are expected to have a higher risk of
morbidity in case of a seriously affected family member,132–135
although the extent of risk for the family members of affected patients
is not yet clear.136–138 At the same time, raising awareness among
health practitioners about detecting early symptoms of HH has been
promoted.123,139,140 Studies from the United Kingdom and the Neth-
erlands show, however, that often patients showing symptoms of HH
or family members of HH patients are not yet being offered a test,
despite protocols that recommend testing.134,141 Therefore, in families
where the mutation has an impact, hemochromatosis is still under-
diagnosed. Possibly medical specialists are not used or inclined to deal
with the familial aspects of the disorder, or are less prone to focus on
prevention. In that case, closer contacts with clinical geneticists might
prove helpful in educating health-care professionals and organizing
better screening and case detection practices.
Powell et al135 state that the most cost-effective methods of early
case detection are family (cascade) screening and evaluation of
potential cases by primary-care physicians. Pietrangelo142 also points
to the role of primary care and the importance of screening patients
for iron overload. He estimates that it will be possible to extend this
screening to all patients seen in primary care: ‘The rationale is similar
to that for routine cholesterol screening and the prescription of dietary
restrictions and drug therapy when risk is verified in the absence of
signs of CVD. When the results of iron-metabolism tests are abnor-
mal, clinical biochemical values should be monitored; if genetic tests
are positive for HH, prophylactic iron depletion should be considered.’
Njajou et al143 also propose a two-phase population screening
program, based on establishing serum iron levels biochemically and
then a genetic test for people with elevated serum iron parameters.
Genotype-based screening has also been reported to be cost
effective. For example, the above-mentioned German pilot study
was aimed at insurants of a sickness fund who were tested for the
C282Y mutation.130 Recently, a systematic review concerning geno-
typing for the C282Y mutation underscored that DNA testing for HH
in at-risk populations has clinical validity and may have clinical utility;
in addition, two studies suggesting cost effectiveness were found.
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However, the review highlights the limitations of the literature and the
methodological difficulties associated with evaluating this genetic
test.144 For Germany, a recent review discusses the cost effectiveness
of different strategies of detecting patients via cascade screening,
population screening, and genotyping.145 It confirms the cost effec-
tiveness of the current German policy to screen only for at-risk
individuals, but suggests to conduct a DNA test after elevated iron
levels have been found, instead of performing two transferrin satura-
tion tests.145
Finding, counselling and testing sibs is a time-consuming and
specialized activity. If the numbers of people applying for testing
increased (as is expected to be the case for HH and for other disorders
for which an important genetic component will be established),
current facilities for testing and counselling may not be adequate,
either in primary care or in specialized medical care. More systematic
approaches might be organized in diverse ways, depending on the
health-care organization and system and practices of referral in a
specific country.
In the Netherlands, it has been suggested that the model used by the
Foundation for Tracing Hereditary Hypercholesterolaemia (StOEH)
might be appropriate for HH as well.142 In considering cascade
screening as organized by StOEH as an exemplar for susceptibility
screening, it should be noted that screening for FH differs from both
susceptibility screening and screening for HH. The fact that FH is a
highly penetrant autosomal dominant disorder favors the effectiveness
of cascade screening.
In tackling the question of how to improve contacts between
primary and specialized care, and how to optimize the system of
referral of patients, it is not enough to address the knowledge gap
between family doctors and specialized care. Indeed, knowledge about
genetics is lacking.147 However, better knowledge might not be
sufficient for referral and follow-up. Primary care may have its own
practical considerations and interests that need to be understood and
considered.32,148 In making better use of genetic knowledge for public
health purposes, not only knowledge transfer but also practice needs
to be taken into account. Intermediary organizations such as StOEH,
as well as intermediary professionals, such as genetic nurses and
genetic field workers, and, last but not least, professionals active in
the clinical genetic setting, such as genetic counsellors, might be
helpful in bridging the gap between primary care and specialized care.
THE ECONOMIC EVALUATION OF GENETIC TESTS
Genetic testing for screening purposes as part of the health-care
system typically aims at preventing or reducing deterioration in
health. Economic evaluation of genetic tests addresses very hetero-
geneous aspects: the uncertain characterization of genes involved in
the etiology of complex diseases, the partial knowledge about which
people are at increased risk and about the likelihood that an inherited
predisposition may result in the development of disease, as well as the
incomplete potential to predict the effectiveness and cost of an
intervention.
As previously mentioned, the evaluation of a health technology
such as genetic screening for health purposes can be conducted by
instruments specifically directed at the technology of screening, like
the WHO criteria established by Wilson and Jungner,22 or at the
health-care setting and the genetic disease, like the ACCE11 or the
EGAPP149 framework. Specific instruments are usually highly sensitive
to the character of the technology under investigation. The clinical
utility domain of the ACCE framework explicitly includes economic
evaluation. Alternatively, more generic health economic methods150–152
that have been applied to a broad range of health technologies can and
have also been applied to evaluate genetic tests.153 Health economic
evaluations explicitly take into account the consumption and savings
of scarce resources implied by the application of a health technology.
In addition to the question of whether or not a technology can be
considered effective, they provide guidance on whether the investment
in this technology provides sufficient value for money as compared
with alternative available uses of a given budget.
The present chapter is dedicated to the assessment of genetic testing
by health economic evaluations and the appropriateness of genetic
tests for screening programs that might also be derived from those
evaluations. The major tasks of economic evaluations are to identify,
measure, value, and compare the inputs (costs) and outputs (effects)
of the alternatives being considered.154 Given the limited healthcare
resources in general and in particular the consequent inability to
produce all desired outcomes – or even implement all efficacious
therapies – choices must be made concerning the implementation of
genetic testing services. Thus, economic evaluations of genetic tests
can help to ease the decision-making process by providing informa-
tion about both costs and consequences of alternative courses of
action, as well as their appropriateness and utility in the context of
genetic screening programs.
Effectiveness and cost effectiveness of genetic testing and screening
Health economic evaluation is increasingly used to inform policy
makers about prioritizing calls on a constrained health-care budget.
The requirements for full economic evaluations include the need to
consider all appropriate evidence, to compare new technologies with
all relevant alternatives (in terms of costs and consequences), and to
reflect uncertainties within the analysis.152 Early identification of a
disease predisposition conferred by a genetic polymorphism might
help to lessen suffering and premature death while reducing the costs
of medical treatments and therapies.155 Systematic screening programs
are more likely to be cost effective if a disease is relatively common or
the risk for disease sufficiently increased. At the same time, genetic
tests (that reliably provide information about an individual’s suscept-
ibility to disease) as well as effective treatments for the predisposed
disease have to be available.
Effects. The starting point of health economic evaluations is to assess
a technology’s benefit and to determine whether the benefit outweighs
its potential health-related harms. A general difficulty in identifying
and assessing an initial genetic test originates in the fact that test
results in the first instance represent no primary clinical effects but
intermediate outcomes. This is caused by the fact that they can only
help in determining an appropriate treatment or prevention leading to
final health outcomes. Evaluations as part of the assessment of the
clinical utility usually deal with final health outcomes that can be
measured either in natural units (eg, life-years gained (LYG)) or in
preference-based measures (eg, quality-adjusted life-years (QALY)).
Genetic susceptibility screening in common disorders aims at offering
opportunities for early diagnosis, preventive (primary or secondary)
strategies, or informed choice. The result of a single genetic test may
allow for a more personalized treatment being applied in case of a
(true) positive test result. At the same time, it may produce changes in
the tested individual’s behavior, bringing about a totally different
lifestyle. Also, the impact of knowledge about genetic status on a
patient’s quality of life in general and on his or her emotional,
physical, and social situation in particular has to be considered.156
The effectiveness of a genetic test is determined by the prognostic
significance of the test result. This has to be distinguished from the
efficacy, which is described as the diagnostic ability of a genetic test,
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that is, the ability to accurately detect the genetic variation it was
designed to identify. For the economic evaluation of genetic tests, it is
the effectiveness that has to be factored into the analysis, which –
besides the availability and effectiveness of prevention – depends on
the degree of association between a genetic variation and the physical
manifestation (phenotypic characteristic). The penetrance of a genetic
variant itself has an impact on both the clinical and economic
outcomes.157 The same goes for the sensitivity and specificity of a
genetic test: The more sensitive and specific a test is, the more effective
it is regarding potential clinical benefits. An advantage of (full)
economic evaluation is the consideration of characteristics beyond
the mere sensitivity and specificity of a genetic test. The general aim is
to measure all effects on health to determine all benefits of a test’s
implementation even if the intermediate effect (ie, the test result) has
no impact on patient-relevant effects (eg, LYG).
Another unknown factor is the potentially harmful behavioral
change caused by the impact of knowledge of genetic status on the
tested individual’s behavior:157 Patients with identified genetic variants
might exhibit a change in behavior, while patients with no major
genetic variants identified might adopt a more careless attitude with
regard to their lifestyle and the exposures potentially related to disease
risk. Regarding common disorders with a considerable impact of
environmental factors on the disease onset, this might prove counter-
productive if exposures have a higher effect on the development of
disease than the genetic predisposition. If people who have been tested
within the scope of a genetic screening program obtain a negative test
result, the development of an adverse behavior would again increase
the burden on the health-care system because a shift of risk occurred –
from the subgroup of genotypic high-risk individuals to environ-
mental high-risk individuals.
To facilitate a meaningful health economic evaluation of genetic
tests, the effects of testing have to be established in terms of end points
that are relevant to patients and decision makers. Different approaches
have been proposed to capture such benefits. According to the ACCE
framework, the clinical benefits can be evaluated within the scope of
the analytic validity and clinical validity, which address a broad range
of aspects, including cost effectiveness and the impact on quality of
life. However, it has been claimed that considerations regarding the
clinical utility should not only refer to clinical end points but also
include psychological, ethical, legal, and social issues, because ‘they
contribute to the net balance between benefits and harms of genetic
testing for tested individuals, their families, and the population at
large’,158 so that the term ‘clinical utility’ may be too narrow to capture
the range of decision-relevant benefits and harms. The patient-
relevant end points for evaluating the usefulness of a genetic test
can also be determined by the ability to reduce the population burden
of morbidity, mortality, and disability.159 Khoury et al79 defined the
benefits from a reduction of disease burden in the population (based
on genomic profiling) as public health utility. Thereby, the population
impact is expressed, implying that the reduction in disease burden can
be measured after removing the exposure responsible for the disease
burden. However, a test applied to identify gene mutations in a large
proportion of the population is not necessarily useful.35
To quantify the magnitude of improvements in health outcomes in
a way that makes it comparable to the magnitude of costs in a cost-
effectiveness analysis, it is necessary to apply a cardinal and, if health
gains are compared across conditions, a generic measure (eg, QALY,
LYG, etc) to combine the impact of disease, disability, and premature
death. Besides the potential effects of genetic testing on the quality of
life – due to early identification of disease-associated genetic variants
and taking appropriate measures to reduce morbidity – there may also
be effects on life expectancy. These effects depend on the individual’s
age at the time of the test (or potentially the time of the diagnosis), the
treatment options, and the therapeutic outcomes. The onset of
symptoms can be delayed or even avoided and the quality of life (at
this point, ie, the overall assessment of the excellence of a life)
observably improved. As the long-term prognosis for patients with
genetic disorders improves over the coming years as a result of
expected advances in treatment, so also will the effectiveness of genetic
testing services increase.
The effects of genetic testing are subject to uncertainty. Given that,
typically, no single study is available that establishes the long-term cost
effectiveness of a screening program as a whole; modelling has to be
utilized to provide a structured quantitative synthesis of the evidence
of different aspects of screening (eg, test sensitivity, health effect of
prevention, adherence to prevention), including their joint parameter
uncertainty.
For tests that have no tangible health effects but may nevertheless be
of positive outcome to patients and consumers, benefit may also be
captured in terms of the individual’s willingness to pay (WTP). It has
been proposed that WTP may be a better outcome measure than
attempts to establish clinical effects.160 However, in the face of scarcity,
there are competing uses of health-care resources across a wide range
of conditions, including, for example, new treatments for severely ill
cancer patients. In such a competitive situation, it is unclear whether
health-care payers decide in favor of funding for a large number of
upcoming genetic and genomic tests with unproven clinical benefit.
Therefore, clinical utility is likely to remain of high importance in the
evaluation of genetic tests.
Costs. The costs that have to be considered in the economic evalua-
tion of genetic testing and screening can be split up into medical
resources consumed by the health-care intervention (direct medical
costs or other non-medical resources consumed by the intervention
(direct non-medical costs, eg, travel cost)) and productivity losses (if
an individual is absent from work and is therefore not able to
contribute his or her usual productivity).
Direct medical costs include costs for test kits used to obtain
primary results and to eventually confirm those results. Because
economic evaluations always have to compare alternative options,
not only the costs of a genetic test but also the differences between the
testing alternatives and the differences in treatment costs (depending
on individuals being tested or not) have to be considered. Further-
more, staff costs need to be considered, which refer to the workload
caused by a genetic test, including the costs of genetic counselling, if
needed.
Whereas the costs for test kits as well as costs for laboratory staff
and genetic counsellor costs can be rather easily assessed, the treatment
and follow-up expenditures are of greater complexity; they might
exceed the direct costs for purchasing the test notably. This may
include a range of unnecessary follow-up testing in case of positive test
results, even if tests are directly provided to consumers at no initial
cost to the health-care payer.161 Frequently, the efforts required for
additional medical care and follow-up are not known at the time of the
test, so that only rough estimates of future costs are possible.162
Additionally, problems may occur when introducing new screening
programs into clinical practice. If adequate requirements at system level
are not fulfilled and new structures have to be introduced (to identify
the appropriate target group, implement screening, provide counselling
or support if needed), additional costs might result, as well as a
decrease in the potential health impact, which should be considered
in a comprehensive evaluation of genetic screening programs.
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Cost effectiveness. The decision about whether or not to perform a
genetic test emanates from consideration of the consequences, includ-
ing the benefits (outputs) and costs (inputs) of alternative medical
interventions. The results of economic evaluations can only be
interpreted by reference to an external standard (such as the result
from other, independent programs, the cost-effectiveness threshold
reflecting the value for money of the existing programs).
Four types of economic evaluations can be distinguished:
(1) Cost-minimization analysis (CMA) compares only the costs of
treatment alternatives. CMA is used in situations where two
interventions are known to incur equal health outcomes. This
could be the case, for example, for different laboratory proce-
dures delivering genetic test results with equal sensitivity and
specificity. However, typically treatment alternatives differ not
only in terms of costs but also in terms of effects.
(2) Cost-effectiveness analysis (CEA) establishes the cost per health
outcome for the treatment alternatives measured in natural units
(eg, cases detected or LYG). This can be used, for example, in the
comparison of different screening strategies for a hereditary
disorder like hemochromatosis.145 CEA is the most frequently
used form.
(3) Cost–utility analysis (CUA) assesses the cost per outcome mea-
sured in utility values (eg, QALYs). Besides a comparison of
different screening strategies within one medical condition, they
can additionally be used to compare the cost effectiveness for
very different screening programs or other medical interven-
tions. This can then be used to establish whether the allocation
of funds for this test provides a higher benefit than alternative
uses of the scarce resources.
(4) Cost–benefit analyses measures the effects of tests in terms of how
much individuals would be willing to pay (WTP) for them. This
allows including non-health benefits into the analysis. Also, it
allows for a comparison of value for money beyond the health-
care sector.
In a very broad review of economic evaluations of genetic tests,163
more than half of the 62 economic evaluations were CEA. The
remainder were CUA as well as analyses based on a comparison of
testing costs with costs potentially avoided, particularly owing to
terminated pregnancies after diagnosis of severe hereditary disease.
These analyses are frequently termed cost–benefit analyses; given that
they are restricted to a comparison of costs rather than assessing
benefit in terms of WTP, CMA may be an appropriate term.
To assess the methodological quality of economic evaluations,
guidelines have been developed, for example, a checklist by Philips
et al164 for evaluations based on decision analytical models or the
CHEC list by Evers et al165 for trial-based evaluations (see also
Appendix B).
Given time and resource constraints, it seems hardly possible to
evaluate most of the genetic susceptibility tests extensively. A key
question – regarding genetic testing in common disorders under
public health auspices – that has to be answered is whether the
clinical validity of testing for common disorders will be sufficient to
warrant the use of limited public funds for both testing in healthy
individuals and further research (eg, large-scale genome-wide associa-
tion studies).166
Given that an increasing number of genetic tests are easily available,
for example, via the internet for private use (ie, ‘direct-to-consumer
genetic testing’ (DTC)), a second key question is to evaluate the
potential harms of tests for testing or screening purposes. The more
the tests are available due to a direct-to-consumer advertising, the
more likely it is that market mechanisms (ie, competition, individuals’
WTP) will regulate the uptake of genetic tests, which may also lead to
problems of uncertainty and information asymmetry, which are well
known to distort markets in the health-care sector.167 Especially in the
case of common disorders and the need for identifying more than one
gene variant or disease-causing mutation, a simple risk prediction is
very likely not to be sufficient. This is caused by the fact that
counselling might be indicated in some cases and/or that genetic
testing in common disorders with low penetrance cannot completely
predict the risk of disease (onset). Here, evaluations of genetic tests to
identify (potential) effective and efficient genetic tests as well as
evaluations of potential harms may be necessary to help policy makers
develop market regulations that protect individuals’ health and the
social welfare.
The health economic evidence base for genetic testing
for common disorders
This section is about identifying the health economic evidence on
DNA-based testing and screening in common disorders, including the
‘monogenic subset’ of diseases within this group. Genetic tests that
were considered are those that involve DNA-based genetic testing
(aimed at detecting specific variants in the DNA sequence).41
The area under investigation was a number of recently
published reviews covering economic evaluations of genetic
testing.155,163,164,168–170 An additional conference poster presentation
updated the economic evaluations of pharmacogenetic tests.171 Given
the intentions of a NoE to consolidate existing research rather than to
conduct original studies, this review draws upon the studies quoted
above. All evaluations mentioned were extracted (evaluations of
prenatal testing were excluded), and we assessed whether the studies
met the definitions given in the previous chapters. The types of
economic evaluation most commonly used in this context are cost-
effectiveness analysis (results represented in costs per LYG) and cost–
utility analysis (results represented in costs per QALY). The main
factors determining the cost effectiveness of genetic testing in common
disorders were the prevalence, mortality risk, and the test costs.
The health economic evidence on genetic screening is limited
because only few conditions have been properly evaluated. None of
the identified reviews explicitly targeted genetic polymorphisms. To
account for potentially omitted or recently published studies, a
complementary search targeted the intersection of the concepts ‘health
economic evaluations’ and ‘polymorphisms’ in several databases
(PubMed and Cochrane, including the Centre for Reviews and
Dissemination databases DARE, NHS EED, HTA). Given the high
quality of PubMed indexing153,172 and large difficulties in representing
an unknown number of conditions and mutations in a systematic
search, this query was conducted by Medical Subject Headings. Details
of the search are given in Appendix C1. All studies of common
disorders identified by extraction of reviews or the supplementary
search are given in Appendix C2.
The query revealed that hardly any health economic evidence exists
that supports the clinical utility of DNA-based testing and screening in
common disorders with low penetrance (see Appendix C2). Most
research done so far considers rare diseases or the highly penetrant
‘monogenic subset’ of diseases within this group (eg, breast cancer).
The findings generally confirmed the results of a study by Rogowski
and Langer155 dealing with genetic tests and their application in
screening programs, which revealed that only screening for rare
diseases – familial adenomatous polyposis (FAP) and retinoblastoma
– has been calculated to be cost saving. Regarding FAP, the financial
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benefits mainly arose because close relatives who are negative for a
causative mutation identified in the index case were excluded from
increased colonoscopy and sigmoidoscopy on the basis of a positive
family history. The effectiveness of genetic testing for retinoblastoma
in relatives was shown by a comparison with conventional screening
using ophthalmological examinations under a general anesthetic.
Testing a family member in this case is comparable to a cascade-
screening approach. In addition, the cost effectiveness of systematic
screening for genetic contributors to hereditary non-polyposis color-
ectal cancer is likely to fall below the typically cited benchmark values,
provided that certain criteria for diagnosis are applied (eg, Amsterdam
criteria, Bethesda criteria). After immunohistochemistry testing, test-
ing for HNPCC mutations may also have favorable costs per LYG in all
patients with colorectal cancer.173
Evidence for the benefit of a population-wide screening for heredi-
tary diseases, for example, hereditary breast and ovarian cancer, was
generally weak. If at all, screening may only meet the frequent
thresholds of cost effectiveness in case of specific populations in
which a founder effect is present, for example, in the case of BRCA
screening in Poland.174 Also, many of the studies may be outdated
because they do not account for the currently much lower test
costs than years ago, but equally not for the most recent evidence
of effectiveness. The evidence on screening for FH is partly contra-
dictory; the comparable studies proved the effectiveness of phenotypic
screening.
The values per LYG or QALY could diverge widely. Partly, this may
be because of weak epidemiological evidence. Before the evaluations
can be used in decision making, the results have to be examined more
closely to determine whether they are due to differences in the study
design or due to different health-care settings that might influence the
cost per LYG. Especially against the background of the historical
development of different health-care systems, differences in the
evaluation of health-care benefits and in thresholds for the imple-
mentation of new interventions seem evident.175
But as it is complex – if not impossible – to fully evaluate all or even
most of the genetic susceptibility tests that are available, given the
limited funds for health care and health research, also applied research
for novel genetic tests needs prioritization.173 Criteria for selecting
tests may include the penetrance and prevalence of the specific
disorder, as well as the nature of the test, its purpose, and the
population in which it is to be carried out. This may imply that
tests for common disorders (with higher prevalences) are more likely
to be assessed than tests for rare disorders, as the costs for a full
evaluation are better justifiable because of the higher number of
individuals involved,93 at least if there is some prior probability of
the tests being cost effective. Given the results of recent genome
research and the search for major risk factors in common disorders,
we noted that only a small proportion of the total genetic risk can be
accounted for by the risk factors identified to date.176 The genetic
heterogeneity of multifactorial disorders poses the challenge of dis-
tinguishing disease-causing variants from functionally neutral ones.
The association between a genetic variant and the respective disorder
has to be sufficiently established by genetic epidemiological studies: as
long as no evidence exists on the effectiveness of genetic testing in
common disorders, the evaluation of cost effectiveness is not likely to
produce meaningful outcomes. And yet, after its initial introduction
onto the market or into clinical practice, the performance of a genetic
test with sufficient priority for further research should be assessed over
time. Ideally, this has to include a pre-market review (to ensure a test’s
potential to achieve its purpose) as well as a post-market assessment
(to guarantee adjustments if needed).
The identification of new risk factors has not yet revealed many
novel insights into the pathogenesis of common diseases, as associated
markers were usually found in non-coding regions or in genes with
unknown function. Furthermore, the limited resolution of association
and linkage analysis so far has led to the fact that responsible sequence
variants could not be precisely mapped.176 If this challenge of precisely
mapping disease-causing variants was met, the evaluation of appro-
priate genetic testing would be associated with a lower level of
complexity and uncertainty and the effectiveness of genetic tests
could be assessed more easily – as can be observed in Mendelian
disorders up to now. The health economic evidence on DNA-based
testing and screening in common disorders focuses on the Mendelian
subsets of common diseases. It is particularly noticeable that even with
full HTA reports not all aspects (among others, clinical, social, ethical,
economic aspects) are considered when evaluating genetic tests.
Especially the lack of social and ethical considerations stands out,
given the special importance of these issues to that part of the
population being offered genetic screening or testing. Therefore, it is
crucial to take a closer look at social and ethical aspects in addition to
medical and economic considerations.
However, only a small proportion of individuals will possess the
constellation of genotypes needed to increase the positive predictive
value significantly. Furthermore, the complexity of genetic and envir-
onmental interactions and the interdependence of varying risk factors
might never be represented in association studies.177 Thus, to screen
entire populations for genetic susceptibility to common diseases under
public health auspices would be very expensive and potentially even
harmful.
GENETIC TESTING AND SCREENING FOR COMMON
DISORDERS IN HEALTH CARE: ETHICAL, LEGAL, AND SOCIAL
ISSUES
Around the turn of the century, debate was going on as to whether the
new genetics would revolutionize health care, or whether an evolu-
tionary perspective should be adopted, in which current service
provision forms the basis for new or additional services.178,179 In the
United Kingdom, for instance, the government White Paper ‘Our
inheritance, our future: realising the potential of genetics in the
NHS’180 built on the current system of referral via primary care to
specialized clinical genetic services.25 Calnan et al181 state, however,
‘increases in demand will have implications for access and equity and
any serious attempts to integrate genetics into everyday clinical
practice will require major changes in training and clinical practice’.
In recent years, a sense of urgency has developed about issues
concerning the integration of genome-based information into health
care.6,32,76,82,182,183 In Europe, the PHGEN (http://www.phgen.eu) has
been established to ‘promote the responsible and effective translation
of genome-based knowledge and technologies into public policy and
health services for the benefit of population health’. In 2009, the UK
House of Lords Science and Technology Committee published a
report on Genomic Medicine184 calling for a new White Paper, since
developments in genomic medicine moving away from a focus on
single-gene disorders to include common disorders have implications
for health care.
Settings relevant for implementation of testing and screening in
common disorders
Within the health-care settings of many European countries, clinical
geneticists, genetic counsellors, and genetic nurses have a well-defined
task in diagnosing and/or counselling patients with rare genetic dis-
orders and their family members. Recommendations for co-operation
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with other medical specialties and primary care are available, offering
a framework for patient care and referral in daily practice, although
referral is not always optimal.185
Although in many countries clinical genetics has been able to create
a visible and viable position, staff and resources are limited. This will
have an effect on the ability of current clinical genetic services to
absorb large new patient groups should susceptibility testing for
common disorders be proven to be viable.
Depending on the type of disorder, the organization of health care,
cultures of cooperation, and factors such as scale or population
density in certain regions or countries, genetic information may be
incorporated into existing practices. Other circumstances may favor
the setting up of intermediary or overarching organizations to support
individual health professionals in using genetic information.
Moving away from clinical genetics to other medical settings. To some
extent, for certain forms of genetic testing and screening, settings other
than clinical genetics are already functioning, and communication and
division of labor between these settings and clinical genetics are well-
established.
For instance, in newborn population screening programs, the blood
test is performed on babies in the maternity wards of hospitals or at
home, the lab results are communicated to pediatricians, and the
clinical geneticist would only be involved for certain types of disorders.
However, from a clinical genetics point of view, it is not always clear
whether counselling and informing patients in the pediatric setting is
adequate. Newborn screening is a genetic screening program orga-
nized as a public health intervention program.
For clinical care regarding monogenic subforms of common dis-
orders, an example is provided by the diagnosis and treatment for
breast cancer. Germline BRCA1 and BRCA2 as well as HER2 testing in
tumors has been implemented in regular health care provided by
oncologists in cooperation with clinical geneticists (as stated in the
section ‘Testing and screening for common disorders in Europe’).
The setting up of registries for monogenic subforms of common
disorders provides an example of the formation of a new type of
organization that supports and optimizes current division of labor
between different health-care settings and that integrates genetic
testing in current health-care practices. Practical circumstances related
to scale and patterns of cooperation, as well as legal impediments such
as privacy regulations, may hinder the formation of registries in some
countries.
For common disorders, primary care, most notably family doctors,
have an important role in selecting and treating people who might be
at risk. For instance, in primary care, for hypertension or measuring
cholesterol, tests are provided and patients are monitored. In recent
years, a stronger focus on prevention in primary care has been
suggested in order to tackle the expected rising disease burden caused
by common chronic disorders in an aging population.186 To stimulate
prevention, special consultation offered by trained personnel, such as
nurse practitioners or physician assistants, may be integrated into
primary health-care services.148 Genetic testing or screening for
common disorders such as diabetes and coronary artery disease
might be added to the existing procedures and a close cooperation
between primary care and specialist care could be set up or intensified,
when necessary.
Moving from traditional medical to commercial direct-to-consumer
settings. In recent years it has become possible to obtain genetic
tests for specific disorders in a commercial direct-to-consumer setting
(DTC).187–189 Three different routes for direct-to-consumer tests may
be distinguished. On the one hand tests are sold over the counter, for
instance by pharmacies. Another form is presented by tests available
on the internet. The client can obtain information on the website
about the aim of testing and the meaning of the test result. For some
tests sold on the internet, forms of counselling or contact with a
physician are offered,190 for instance by phone or email. Other tests
may be marketed via alternative health-care providers and consumer
outlets such as sports centers and high street stores.
Especially in the United States, but also in European countries,
commercial laboratories or companies offer tests on the internet, and
the number of providers and tests is rising rapidly191,192 (see also
Table 5 in Appendix E for a list of companies offering direct-to-
consumer genetic testing). The tests range from single-gene tests for
monogenic disorders or monogenic subsets of common disorders,
such as BRCA1 and BRCA2, one or several SNPs or genetic variants
found to be associated with common disorders such as diabetes,
genomic profiles combining gene variants or SNPs, or genome-wide
scans for a particular range of conditions such as cancer or cardio-
vascular problems,193 but which may also be used to learn more about,
for instance, ancestry or traits.187,194 Even a test based on whole-
genome-sequencing techniques can be commercially obtained, which
is costly, although prices are dropping.195
A major problem with DTC tests is premature market-
ing.48,187,194,196,197 Research results suggesting associations between
gene variants and common disorders are sometimes immediately used
to develop and offer a test. As discussed in the section ‘Common
diseases’, information on analytic validity alone is insufficient to assess
the usefulness and performance of a test in medical services. Especially
in case of common multifactorial disorders, the predictive value of
gene variants or sets of gene variants will be low. By commercial
valorization of research findings outside the medical domain, the
established procedures for safeguarding sound assessment and estab-
lishing utility and cost effectiveness are circumvented.
Sometimes companies state that the medical and DNA data will be
used for research, and in some cases clients are stimulated to share
their experiences with other users. Knowing one’s genome becomes
part of a ‘recreational’ genomics.48 The boundaries between the
research, the medical, and the recreational domain become blurred.198
In this way commercial initiatives may bypass not only the services of
health professionals, but also the carefully established ethical standards
developed for the medical domain, considering potentially psycholo-
gically and socially harmful disclosure of knowledge about one’s
genetic make-up. Also, the concept of confidentiality, implied in
meticulous consent procedures in medical practice and biomedical
research, may become overhauled. We can only learn how individuals
will deal with diverging types of genetic information with experience
over time. Especially in case of the profiling services, it is possible that
groups of active ‘early adopters’48 will develop ways of dealing with
this kind of information and pave the way for a larger audience
interested in knowing more about their genetic constitution.
As far as blurring boundaries are concerned, it should also be noted
that the commercial sphere should not be regarded as an isolated
dimension. For instance, spin-off companies often have their roots in
academia; some researchers are active both in a commercial and in an
academic setting; sometimes research, also in academia, is partially
paid for by industry; and also health-care professionals may be
involved in commercial companies. Moreover, data sharing between
commercial companies, academia, and health-care institutions has
become an interesting way of increasing research potential, which
stresses the need to further address issues of informed consent and
confidentiality.198
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Some of the problems with DTC tests relate to the role of the
medical professional. It is unclear whether patients receive adequate
counselling either before or after performing the test, whether they
understand the test results correctly,189 and how the specific test relates
to the overall health status of a person and his or her other health
problems. Physicians claim that the interpretation of test results, and
combining various forms of health information over a longer period
of time, always requires a medical professional. The fact that some
commercial companies include a counselling session or referral to a
physician only partly tackles this objection.199 Problems might occur,
for instance, regarding documenting the information in the patient’s
file, or because of the possibility of bias on the part of the physician
who is paid by the company that sells the tests.
In addition, providing genetic services outside the traditional
domain of medical genetics departments may challenge the public
health-care system. DTC services may stimulate consumers to visit
health-care professionals after an assessment of their risk of developing
a disorder.200,201 Almost all DTC companies state in their disclaimers
that the information they provide is for informational purposes only
and that consumers should contact their physicians to act upon the
test result.202 Therefore, there is a potential risk of overconsumption of
health-care services.
Moreover, consumer genetics are organized in such a way that there
is no control over the origin of the samples being analyzed. Most
companies send mouth swab kits as these are easier and more practical
than having to send the client to a clinic where blood is drawn. As the
mouth swab is done in the privacy of the client’s home, there is no way
of controlling for the identity of the sample provider. Testing of third
parties, such as incompetent minors or incapacitated adults, becomes
possible and rather impossible to control.203 In addition, it has been
shown that some DTC companies test minors without specific ethical
concerns.204
In the United Kingdom, the growing offer of commercial genetic
testing has been the subject of attention for the Human Genetics
Commission, who issued the report Genes Direct in 2003.205 A follow-
up of this report and revised recommendations were published in
2007: More Genes Direct.190
The recommendations in this report relate a.o. to the evaluation of
the evidence used by manufacturers in the marketing of these tests.
This plays a part both in the process of pre-market review and
licensing procedures before the test comes to market and in the
subsequent advertising and promotion of the tests and testing services.
In 2003, as well as in 2007, it was underscored that certain genetic tests
should only be offered by a suitably qualified health professional.
In 2007, the American Society of Human Genetics issued recom-
mendations regarding direct-to-consumer genetic testing.206 They
include the provision of adequate information on test characteristics,
the strength of scientific evidence, limitations to the claimed benefits
of testing, such as other factors involved in developing the disorder,
and the psychological risks. Tests should have adequate clinical
validity, and claims in advertisements should be truthful. It is
recommended that more research is needed regarding the impact of
this type of testing on consumers.
In Europe, the currently available pre-market evaluation procedure
does not cover genetic tests adequately (see also the section ‘Regula-
tory issues’). Commercial tests are subject to certain forms of quality
control and lab standards, and some degree of self-regulation exists.
However, especially in the case of internet offers, it is not clear how
this – internationally operating – sector can be or should be regu-
lated.188 Recently, more pleas for self-regulation or codes of conduct
have been voiced.207,208 In 2009, the UK Human Genetics Commis-
sion proposed a common framework of principles for direct-to-
consumer genetic testing services.209 It was accompanied by a public
consultation to elicit comments and enable establishing priorities in
governing direct-to-consumer testing that can be supported by
stakeholders both in the United Kingdom and in other countries.
One of the aims was to lay the foundation for an international code of
practice for professionals and companies offering DTC tests.
In order to organize and fund pre-market assessment, a combined
effort of stakeholders is recommended. The European Diagnostic
Manufacturers Association may serve as an example of self-organiza-
tion (or function as a platform) to unite the industry and stimulate
interaction with regulatory bodies in drawing new guidelines. This
kind of initiative might stimulate ways to reconcile the drive for
valorization of research findings with responsible entrepreneurship.
For the European context, it is important to find a balance between
protecting citizens against potentially harmful tests on the one hand,
and the right of citizens to obtain knowledge about their health status
and genetic constitution on the other hand. This balance might be of a
different character for Europe and the individual countries concerned,
than for the United States.
In the Netherlands, the Health Council issued a report on screening
in which the role of the government regarding commercial genetic
tests was discussed. Government responsibility was not seen to be
limited to tests that – because of proven benefit for public health –
would merit integration into an official population screening pro-
gram.210 It was advised to organize the development of an official
quality marking, endorsed by stakeholders from industry, profes-
sionals, and governmental bodies. Information regarding the quality
of tests, as well as the pros and cons of testing, should be made
available to the public, for instance through an official website.
Furthermore, it was acknowledged that people should be free to
order commercial tests that are found not to be harmful, if people
pay for them themselves.
The role of patient organizations in commercial testing requires
special attention. There is a potential danger in close connections
between patient advocacy groups and industrial organizations that
want to promote a certain test or medicine. On the other hand,
direct-to-consumer test offers are seen by some as a means of patient
empowerment. Patient advocacy groups can play a mediating role in
offering accessible information on disorders and tests and allowing
people to share their experience with testing and living with test results.
A specific subset of commercial genetic tests and services is offered
in the field of nutrigenomics. It is quite a young and complex field,
and applications are not yet clear, although claims sometimes already
suggest practical benefits. The European Nutrigenomics Organisation
describes nutrigenomics as ‘the science that examines the response of
individuals to food compounds using post-genomic and related
technologiesyThe long-term aim of nutrigenomics is to understand
how the whole body responds to real foods using an integrated
approach termed ‘‘systems biology’’’.211
A GeneWatch report questions both the scientific claims about
individual biological differences between people and their response to
food, as well as the social and political implications of individualizing
and commercializing diet advice. ‘The idea of tailoring diets to genetic
make-up is based on a false and outdated view of the role of genes. For
most common diseases in most people, an individual’s risk is not
predictable, because multiple environmental and biological factors
interact.’ Companies ‘are marketing misleading and inaccurate inter-
pretations of people’s genes and what they mean for their health. As
this industry expands and provides multiple and conflicting dietary
advice and products, there is significant potential to confuse and
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undermine healthy-eating messages. Some people may be falsely
reassured that they are not at risk of particular diseases, with serious
consequences for their health. New ‘value-added’ products such as
functional foods are expensive and unnecessaryy’.212
Connections between sciences, medicine, and health care
In reflecting on the wealth of new research data, Khoury et al213 stress
the need for a sustained translational research effort in order to
accelerate the integration of human genome discoveries into health
care and disease prevention. Several phases of translational research,
including clinical trials, guideline development, and dissemination
research, are needed to ensure a safe and effective implementation. On
the other hand, as this section makes clear, many research results are
applied prematurely in a commercial setting, without establishing
clinical validity and utility. Thus, for the testing of several common
multifactorial disorders as well as for gaining insight into psycholo-
gical consequences and the effect of interventions such as lifestyle
modifications, a new sort of social experiment has started: learning by
doing is partly replacing learning by trials.
When concentrating on the health-care setting, it is relevant to
picture the wider societal and cultural framework of newly emerging
technological developments, such as genetic tests. This framework
enables and constrains the possibilities for innovations, and helps to
identify some of the actors and factors relevant for the actual
translation research as proposed by Khoury.
For the successful implementation of a new technological option –
such as a genetic test or genetic screening program – attunement
between stakeholders on various issues concerning the new technology
is necessary.6,214–216 These issues concern the test performance, the
organization and funding of facilities and services, the prospective
users and the demand, the economic evaluation of the testing, as well
as the political and cultural acceptability. This attunement takes place
on and transgresses various levels: the micro-level (the sociotechnical
niche) of a specific lab or clinic; the meso-level (the sociotechnical
regime) formed by already established technologies, practices, suppli-
ers, users, rules, and values; and the macro-level (the sociotechnical
landscape), the relatively stable environment of institutions, material
infrastructure, and economic, social, political, legal, cultural and
demographic relationships. Achterberg et al214 distinguish four types
of actors or stakeholders: scientists in laboratories and clinics; reg-
ulatory, advisory, and governmental agencies; physicians, and profes-
sionals in (public) health care; and patients and their organizations.
This approach offers a tool to understand what kind of interactions
retrospectively have been, or prospectively need to be – put in place
before implementation of certain kinds of testing or screening is
possible. It may be used to identify stakeholders and actively engage
them in setting up systems of self-regulation or inviting them to
establish a code of practice in relation to the use of genetic tests. For
instance, an active group of patients might articulate a demand for
certain kinds of screening. In the absence of such a demand, the
incentive for screening needs to rely more on, for instance, active
physicians, an alert government, or a strong public health authority.
These features would differ not only per disorder but also per country.
This approach can also be used to understand why certain new forms
of screening take a long time to get implemented. For instance, in
many countries there is no regime for preconceptional care, so new
preconceptional genetic screening cannot be easily added to existing
practices, whereas in the case of certain forms of prenatal screening
current practices can be quite easily expanded.217
Picturing the wider societal and cultural framework of new genetic
technologies may also be helpful in devising scenarios.218,219 For
example, a scenario for dealing with an increasing offer of and demand
for commercial genetic testing might be that clients inform their
family doctors about the test results and that commercial tests will be
integrated into an already existing entrusted doctor–patient relation-
ship. In this view, commercialization is seen as a means of giving the
patient more control over his or her health status, making them
‘copractitioners’ or ‘comanagers of their health’,220 and thus as patient
empowerment. Another scenario would be that commercial testing
expands alongside the official health-care system. People who can
afford – or are anxious enough – to test, may establish a well-
informed, partly highly anxious group, the ‘worried well’. These people
might pose an extra burden on the existing health-care system because
of frequent questions concerning follow-up of test results. Health
inequalities might be intensified.221
Ethical and social issues
Impact of genetic testing and screening for common disorders. It might
be argued that the ethical and social issues of testing for genetic
susceptibility for common multifactorial disorders differ from the
issues of testing for monogenetic disorders, including monogenic
subforms of common disorders. Janssens and Khoury222 state that
for multiple genetic testing (genomic profiling) the differences ‘lie in
the lower predictive value of the test results, the pleiotropic effects of
susceptibility genes, and the low inheritance of genomic profiles. For
these reasons, genomic profiling may be more similar to non-genetic
tests than to predictive tests for monogenic diseases.’ In this line of
reasoning, issues such as psychological burden, anxiety because of
disclosure to family members, and problems with insurance could
have a less prominent role in susceptibility testing and screening for
common multifactorial disorders in comparison with testing and
screening for monogenic disorders, including monogenic subforms
of common disorders.
For genetic testing in relation to monogenic disorders, including
monogenic subforms of common disorders and cancer in recent years,
an impressive amount of health–psychological literature on risk
perception, stress after testing, fatalism, the impact on family relations,
etc, has been produced.223–227 However, not much social scientific
research has been conducted on testing for common disorders yet. In a
2007 study from the United Kingdom, interviews with patients who
had had a genetic test for thrombophilia suggested that understanding
of the test depended on social background.228 As far as the influence of
testing on behavior is concerned, Pijl et al229 found a modest effect
when communicating familial risk (as a surrogate for genetic testing)
in case of diabetes. People perceived greater control over preventing
diabetes and reported to have eaten more healthily after being
informed about their familial risk and the need for a healthy lifestyle
compared with a control group of people who had only been informed
about the need to maintain a healthy lifestyle. Otherwise, studies on
testing for FH and hemochromatosis might give an indication of
relevant issues.
In Australia, secondary-school students between 16 and 18 years of
age and their teachers and parents had a positive attitude toward
screening for HH, were it to be offered to the school population.230
Yet, positive attitudes may not directly correspond to taking a test
when it would really be offered. Furthermore, it is not clear how
knowing one’s carrier status will be experienced over the years. People
might remember the meaning of the test results incorrectly, and
change their lifestyles inappropriately. Also, people might simply
forget the results, which makes it important that some form of
registration is possible, for instance in the primary-care setting. A
German pilot study in which screening for hemochromatosis was
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offered to clients of a health insurance organization concluded that
screening on the basis of a test for the C282Y mutation was generally
accepted and was perceived as beneficial, although uptake was modest.
Reported negative psychological consequences were rare.131 In 2007, a
study was published on a subset of participants in the Hemochroma-
tosis and Iron Overload Screening Study. In comparing participants
from Canada and the United States, evidence was found of at least one
element of negative emotional response to genetic testing, although it
was not serious enough to affect individuals’ mental or physical health.
Fewer Canadians than Americans were found to experience a negative
response.231 A recent systematic review reported few negative psycho-
social outcomes for DNA testing for HH in at-risk individuals,
although evidence was found to be limited.232
For FH, the perception of parents of the test results of newborn
screening for FH has been studied. Parents perceived the condition of
their child as more threatening and uncontrollable when FH was seen
as a genetic condition than when it was seen as a cholesterol problem.
From this the authors conclude that DNA analysis might result in a
sense of fatalism, adversely affecting motivation to change behavior.233
However, in a study in which the quality of life of FH patients was
measured up to 18 months after receiving the genetic test result, no
important adverse effects on the quality of life were found.234 In a
recent study on preventive behavior, Claassen et al235 found that
genetic information on FH had less consequences for changing life-
style than having a positive family history. This was not due to
fatalism: almost all respondents used medication to prevent cardio-
vascular problems. This is in accordance with findings that informa-
tion that a condition is caused by a genetic predisposition may reduce
the expectation that a behavioral means of coping, such as changing
diet, will be effective, but increase the expectation that medication will
be effective.236
While ethical, social, and psychological issues regarding testing and
screening for low-risk alleles in common disorders might be of a
different character than testing for monogenic disorders, the examples
above suggest that they do merit attention. In some cases misleading
or misinterpreted genomic information may cause harm. Recently,
scientists have warned against the commercial marketing of, for
instance, susceptibility testing for schizophrenia and bipolar disor-
der.237 Another reason for concern stems from scientific research. The
pleiotropic effect implies less direct or predictable effect from a genetic
mutation and might connect preventable disorders with disorders for
which no treatment is available. For example, in CVD, polymorphic
variants in APOE have been found to be associated with variations in
blood levels of lipids, lipoproteins, and apolipoproteins. Testing for
APOE variants may yield information about the risk of developing
CVD. However, one variant of APOE, the e4 allele, has also been
associated with an increased risk of Alzheimer’s disease.238 Future
biomedical research is likely to come up with many more instances,
which might make the use of testing for low-risk alleles in everyday
medical-care settings more complicated than adding just another risk
factor.
The 2009 UK House of Lords Science and Technology Committee
report ‘Genomic medicine’ recommends that the UK Human Genetics
Commission ‘should promote a wide-ranging debate on the ethical
and social issues relating to genetic tests and genetically complex
diseases with the aim of improving the public understanding of
genetic risk and predictive testing in common complex disorders.’184
Counselling. For monogenic disorders, counselling procedures and
adequate provision of information have been studied extensively. It is
not clear yet what type of counselling susceptibility testing would
require, and what would be possible given the limited time frame of
consultations in primary care.239 In the recommendations issued by
EuroGentest regarding ‘susceptibility testing’ (sometimes referred to as
risk profiling’), it was stressed that ‘if the test is or is claimed to be
capable of detecting high relative risk for a serious condition and thus
has significant implications for risk assessment, treatment or preven-
tion in a person or his/her near relatives, then pre- and post-test
genetic counselling is needed.’23 Also, the Council of Europe’s Addi-
tional Protocol to the Convention on Human Rights and Biomedicine,
concerning Genetic Testing for Health Purposes,240 states that coun-
selling could vary ‘in form and extent in accordance, in particular,
with the implications of the test and their significance for the person
concerned or the members of his or her family’.241
In addition to (and perhaps in some cases partly replacing)
counselling, high-quality information can support decision making
by patients on genetic testing services. In the United Kingdom, in the
DISCERN project, an elaborate scheme has been devised to assess
patient information on the basis of criteria applicable to various forms
of genetic disorders,242 which could also be used for testing or
screening for common disorders.243 Easily accessible and high-quality
information may also be of great importance in testing for common
disorders. Websites and organizations currently involved in providing
this kind of information in relation to monogenic disorders, such as
patient advocacy groups, might extend their services to include
information on common complex disorders.
Legal issues. Regarding insurances, again we may turn to screening
for FH as an example. In the Netherlands, a few patients diagnosed
with FH did meet difficulties in finding life insurances.244 Active
involvement of insurance companies with patient groups resulted in
establishing guidelines for offering insurance to FH patients.245 In the
United Kingdom, since 2001 there is a voluntary moratorium on the
use of most genetic test results by insurers, which has been extended to
2014.246 It is a general concern that fear of social and economic
drawbacks might withhold people from obtaining information about
their genetic constitution for health purposes. Genetic non-discrimi-
nation legislation would be important in creating favorable conditions
for genetic testing and screening. Preferably, stakeholders from insur-
ance and other relevant sectors can be stimulated to find common
ground to ensure that both employers and insurance companies use
genetic information in a responsible and ethically justified manner.
Should clinically useful genetic tests for common disorders be
identified, an adequate system of reimbursement for testing and
treatment, and preferably also for prevention, by means of collective
health insurance is vital to ensure that individuals are not excluded
from health care as a result of high genetic risk. In this way, the danger
of furthering inequalities in health care as a consequence of increasing
genetic knowledge may be reduced.
Concerning the marketing of tests for common disorders, many
regulatory issues will need to be addressed. This issue will be dealt
with in the next section.
Research and development of new test devices are costly. Patenting
may be a way to ensure return on investment; however, research may
be hampered by legal restrictions on use and dissemination of genetic
knowledge. A concerted action between stakeholders in industry,
health care, professional and patient organizations, and governmental
bodies is necessary to balance the interests of industry with the
requirements of furthering the availability of testing devices in a
responsible manner (see also the ESHG Background Document247
and Recommendations248 concerning patenting and licensing in
genetic testing).
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When genetic testing or screening would become more prominent
in health-care services for common disorders, current facilities for
storage would be stretched. Storage of samples or tissue and informa-
tion on health and lifestyle of individuals in biobanks may be useful
for research. Legislation is necessary to secure privacy and non-
discrimination regarding the use of genetic information to ensure
an enduring public trust.
Confidence: public understanding and participation. In the literature
on public understanding of technology, since the 1970s the idea of a
knowledge gap between public and science has been challenged. On
the one hand, laypeople and patients do have a distinct and often
relevant form of prior (local, practical) knowledge to which profes-
sional knowledge ought to relate.249 On the other hand, as recent
health psychological research has shown, increasing knowledge does
not always lead to greater acceptance of new technology. In sociology
and social studies of science, this has prompted the notion of
‘upstream engagement’ of the public voice and the need for profes-
sionals to enter into dialogue with the public instead of unilaterally
‘explaining’ new technologies. Entering into dialogue, public engage-
ment, and public consultation is not only seen as essential elements in
gaining knowledge about the public’s perception on and acceptance of
new innovations, but are also seen as central elements of the
functioning of modern democracy.250,251 Perhaps in the United King-
dom, public engagement has found a more firm platform and official
status than in other European countries in the aftermath of public
scandals concerning BSE and GM foods, which were seen to under-
mine public confidence in science and technology.
In the United Kingdom, new initiatives have been taken to enter
into dialogue with the public at large. The Human Genetics Commis-
sion has set up various forms of public consultation – for instance, on
the supply of genetic tests directly to the consumer.190,205 Also, in the
United Kingdom six genetic knowledge parks were active in the field
of public engagement.250,252 For the Netherlands, the Centre for
Society and Genomics has a similar mission of stimulating dialo-
gue.253 To enable citizens to reflect on biomedical issues such as
genetic testing, genetic literacy needs to be stimulated, for instance by
improving secondary education in life sciences.254
Besides on a collective level, confidence has an important role in the
individual doctor–patient relationship. In medical curricula and
health psychology, a similar trend toward taking the patient more
seriously can be discerned. In recent years there has been a growing
experience with the implementation of forms of communication
between doctors and patients, such as shared decision making and
informed decision making, that are highly relevant when discussing
genetic testing options. These techniques are well known in clinical
genetics practice. Clinical geneticists may act as resource persons or
assist in education of other health-care professionals to raise the
standards of these forms of decision making and counselling applied
by these professionals.
Training. Although there is growing evidence that genomics will
change the practice of medicine, the question remains: how. Currently,
health-care providers have deficient knowledge about genetics.147 For
primary care especially, basic knowledge is necessary to be able to
identify patients who require further investigation or referral to a
specialist, and to make communication possible between primary-care
professionals and specialists. Primary-care professionals should also be
able to understand inheritance patterns and communicate this infor-
mation to patients in order to counsel them on issues of risk, testing,
and familial aspects.32
In preparing health-care professionals and students for the emer-
ging possibilities, given the rapid developments in genomic science, it
is impossible to provide a final base of knowledge. Rather, we must
find ways to impart knowledge, skills, and attitudes that will make
students lifelong learners of genetics and genomics.32 In addition,
transparent communication and cooperation structures with relevant
other health-care providers and genetic specialists are relevant to
enable information sharing, referral, and monitoring.
In a EuroGentest Network project, contacts were established with
a.o. the ESHG Education Committee, resulting in several initiatives to
raise the level of education and information regarding genetics among
health professionals. Aworking group was set up to identify minimum
levels of competencies for health-care providers in Europe.255 A
website was established giving information on courses and offering
hyperlinks to national professional groups and organizations.256
Developing countries. Developing countries are a heterogeneous
category of countries in which 80% of the world population live
and are characterized, among many other things, by medium–low
incomes, high degree of economic and social inequality, a high load of
preventable diseases of poverty (infectious and nutritional diseases),
and a rising prevalence of non-communicable diseases, which have
already become the main sources of morbidity and mortality in most
developing nations. Health systems in developing countries are
characterized by fragmentation and under-funding of the public
sector, coexisting with a small private sector that caters to the wealthy
elites with similar levels of spending and high-technology approaches
to health that their equivalents enjoy in developed countries.257 In most
developing countries, the total annual per capita health expenditure
rarely surpasses USD 300, with appalling inequities in access according
to social class. There is no tradition of government oversight of the
quality of health care, and much less of quality of laboratory testing.
All the considerations, caveats, and skepticism detailed in this
report on the relevance, priority, and appropriateness of genetic
susceptibility testing or screening for common disorders in Europe
apply as well to developing countries. Furthermore, and because of
economic and cultural factors, among the latter the priorities for the
control and prevention of common complex disorders should empha-
size ‘generic’ population-wide programs of proven public health
impact, such as tobacco control, healthy nutrition, physical activity,
stress reduction, and avoidance of exposure to environmental muta-
gens, rather than ‘individualized medicine’ based on genetic suscept-
ibility testing. In some special cases, it could be that the prevention of
rare monogenic subtypes of common diseases, such as BRCA1 and
BRCA2 mutations causing breast and ovarian cancer, FH, FAP, and
others that may come in the future, may benefit from cascade
predictive testing in families when the approach is justified by their
population prevalence and where the detection of an index case allows
the proper assessment of the genetic risk in the family. Even within this
scenario, the utility of the information gained has to be assessed before
use. Furthermore, one would have to carefully weigh the relative cost/
efficiency of different available preventive options carefully, as well as
consider the possible detrimental effect of common problems in
developing countries, such as lack of health personnel qualified for
genetic counselling and testing, genetic stigmatization and discrimina-
tion, over-reliance on technology, lack of qualified governmental
oversight and quality control, and lack of a public health system
that can sustain the approach.
For the prevention and control of common complex disorders in
developing countries, much is to be gained by raising the standards of
living conditions (nutrition, avoidance of deleterious environmental
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agents) and access to primary health care. Given the scarcity of
resources and multiple other priorities, the proof of clinical validity
and utility of genetic testing for common disorders in promoting
health with equity and justice is of even more ethical and economic
importance in developing than in developed countries. These princi-
ples should apply as much to the general population of developing
countries as well as to the wealthy minority that make use of private
health care, because in one way or another the expenditure in private
health care tends to drain resources from the overall society. Thus,
regulations and guidelines for the use of genetic testing based on the
evidence of clinical validity and utility are a responsibility that
governments should take seriously to protect their citizens from the
untimely and improper use of unsafe or inefficient predictive genetic
technologies.
Given that globally most research funds come from the for-profit
private industry of developed countries, it is no surprise that diseases
that affect the Western world have received more attention in research.
The lack of development of drugs against scourges particularly
affecting the poor in developing as well as developed countries
(tuberculosis, malaria, Chagas disease, HIV, and many others) can
only be explained by the low interest of the industry in drugs whose
market would be primarily among the poor who cannot afford the
prices of those products. Pharmacogenetic approaches, however, are
now been heralded as a tool to enhance therapeutic efficiency qand
reduce the side effects of some drugs (for example, the metabolism of
the antituberculosis agent isoniazide depends on variability in the
NAT2 polymorphism). Pharmacogenetic testing should be subjected
to high scrutiny, in the same way that this report advocates for
susceptibility testing in general, and these principles should apply to
developing countries as much as to developed countries. Studies on
the genomes of pathogenic organisms have furthermore contributed
to the development of therapy, for instance in the prevention and
therapy of malaria, where the D-xylulose 5-phosphate pathway can be
inhibited by the antibiotic fosmidomycin.258 Techniques used in
genetic and genomic research are also used to develop vaccines.
As a final comment in this section, it should be cautioned that there
is not a single developing country in which the health situation,
economic, social, and cultural factors are exactly alike any other
country. Therefore, in order to be successful, approaches to prevent
and control common disorders should take into account all these
factors (see also Christianson & Modell259).
REGULATORY ISSUES
Genetic tests fall under the broader statutory regime for the regulation
of in vitro diagnostic (IVD) medical devices. This regime is risk-based,
so the degree of regulatory oversight is contingent on the risk
classification of the device. The regime for medical devices is con-
cerned with ensuring the safety and effectiveness of medical devices
and its most powerful tool is design dossier assessment, which used to
assess, prior to the marketing of a medical device, whether the
manufacturer has met the regulatory requirements, including clinical
evaluation to support the intended use of the product as set out on the
product label and in any promotional material.
Ensuring truth-in-labelling and truthful promotion – an honest
account of the strengths and weakness of a test’s performance – can be
thought of as one of the fundamental functions of statutory pre-
market review of devices. For high-risk tests, regulators may set out in
some detail the types of clinical studies that will be required to gain
pre-market approval. Once a device is on the market, it is subject to
post-marketing surveillance and, if necessary, regulators will remove
unsafe products from the market.
Regulation of IVD devices controls the provision of information on
the performance of a device by setting requirements for the data that
are to appear in:
 the technical documentation;
 the label;
 the packaging and any promotional material.
The technical documentation contains the data that may be reviewed
by the regulator; the label contains the performance data required by
the users of the test and any necessary instructions for the safe and
proper use of the test. Claims made for the stated intended use must
be substantiated by adequate performance evaluation data.
This chapter draws on work by Stuart Hogarth and David Melzer in
collaboration with members of EuroGentest, in particular the out-
comes of a meeting about the IVD Directive held by EuroGentest in
2007 and a briefing on the Directive that Hogarth and Melzer
prepared following that meeting. This briefing has been presented to
the regulatory authorities of EU member states, has been adopted as a
EuroGentest report, and will inform future EuroGentest work on the
Directive. Further analysis of these regulatory issues is consequently
being pursued by the legal working group within the Public Health
Genomics European Network (PHGEN).7 They are assessing the
current regulatory state of the art in Europe and, furthermore, trying
to define areas for harmonization.
The IVD Directive in the context of genetic testing
The European in-vitro diagnostic medical devices directive (Directive
98/79/EC)260 and the measures transposing it into national law
constitute the main regulatory framework for genetic tests marketed
in Europe. The Directive regulates the placing on the market and the
putting into service of in-vitro diagnostic medical devices with the aim
of ensuring their safety and performance for patients and users.
The Directive’s scope includes genetic tests, as they are considered
to be IVD medical devices. But, genetic tests that do not have a
medical purpose, for example, genetic tests for forensic purposes, are
not covered by the Directive.
In principle, the Directive contains all essential requirements for
genetic tests, but it covers the product, not the broader aspects of
testing (how testing, as a service, should be regulated – eg, provision of
counselling), as the provision of health-care services is under the
control of individual Member States.
Some issues that might need further clarification in the regulatory
framework of genetic tests under the Directive are discussed in the
sections that follow.
In-house tests. It is recognized that a number of genetic tests are so-
called ‘in-house’ tests. Clarification is required on which in-house
tests are covered by the Directive. Tests that are ‘manufactured and
used only within the same health institution’, are excluded from the
scope of the current Directive. These in-house tests are covered by
national rather than harmonized community legislation. However,
the term ‘health institution’ needs elaboration or definition to
clarify that commercial laboratories are covered by the Directive.
Currently it is believed that many commercial test laboratories
wrongly claim to be ‘health institutions’ and thus claim to be excluded
from the Directive.
There are many open questions around this ‘in-house’ concept:
1. Is there a harmonized interpretation in all Member States?
2. Definition of professional and commercial contexts.
3. What is a ‘health institution’? Can laboratories be health institutions?
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Risk classification. The primary reason that most genetic tests are not
subject to independent pre-market review in the EU is that they are
either not listed in Annex II list A of the Directive 98/79/EC or are not
self-tests and therefore the manufacturer is not required to submit
their technical documentation to a notified body. An international
comparison of device regulations shows that the European approach is
unique. In the United States, Canada, and Australia, genetic tests that
fall within the medical device regulations are all treated as moderate to
high risk – and so are generally subject to pre-market review (in
Australia, some genetic tests are Class II and exempt from pre-market
review). There are a number of reasons for considering that many
genetic tests are moderate to high risk:
1. They are often stand-alone, with no confirmatory test available.
2. They are used for critical clinical purposes, such as for
pre-implantation genetic diagnosis and selecting treatments
(pharmacogenetics).
3. They may have a serious psychological impact (eg, Huntington’s
disease).
4. Many new tests are highly complex, involving multiple alleles or
multiple genes, making interpretation more difficult.
5. If it is a test that is performed in a single reference laboratory, then it
will not undergo informal peer review by the pathology community.
6. New genetic tests carry the risks associated with all novel devices –
unproven performance in the field and lack of familiarity on the
part of users.
‘A major problem identified with the current approach in the Directive
is an apparent lack of consistency in the risk classification of the
products.’191 However, the Directive sets out a number of criteria to be
considered when considering an amendment or an extension to
Annex II:
(a) ‘any relevant information available from the vigilance procedures
and from external quality assessment schemes as referred to in
Article 11;
(b) the following criteria:
(i) whether total reliance has to be placed on the result
obtained with a given device, this result having a direct
impact on subsequent medical action, and
(ii) whether action taken on the basis of an incorrect result
obtained using a given device could prove to be hazardous to
the patient, to a third party or to the public, in particular as a
consequence of false positive or false negative results, and
(iii) whether the involvement of a notified body would be
conducive to establishing the conformity of the device.’260
Furthermore, manufacturers are required to notify new products to
the Competent Authorities, in accordance with Article 10(4) of
Directive 98/79/EC, thus giving the Member States the opportunity
to closely examine and assess any new test and, where necessary, ask
for amendment or extension of Annex II.
But although there is a clear set of criteria, there appears to be little
consistency regarding what is classified as moderate risk and what is
low risk. Thus, Chlamydia tests are in Annex II, List B, but no other
tests for sexually transmitted diseases; PSA is also on List B, but no
other cancer tests, such as the Pap smear, CA125, CEA, etc; there is
one heritable disorder, PKU, but no others.
It can be argued that a list-based approach to classification is not a
sufficiently efficient mechanism for risk classification, particularly for
novel tests, as, in order to amend or extend Annex II, the Commission
must first examine the request and then propose a legislative measure.
Where Member States do not introduce such a substantiated request,
inconsistency can arise. For instance, Gen-Probe’s PCA3 test quantifies
the PCA3 mRNA in a patient’s urine sample as a marker for prostate
cancer and thus performs exactly the same clinical function as the PSA
test, yet it has not been added to Annex II, List B, despite the fact that
PSA is in Annex II, List B.
The proposed GHTF model: The risk classification schema developed
by the Global Harmonisation Task Force appears to be both more
comprehensive and more consistent.261 Largely modelled on the Aus-
tralian system (itself a refinement of Canada’s model) it is a four-class
system running from high- to low-risk. The risk class of a test is assessed
using a number of criteria, such as the intended use/indications for use,
the skill of the user, the degree of reliance placed on the test result, and
the potential impact on public health and the patient.
The GHTF model places some genetic tests into the moderate-to-
low risk category (Class B) and others in the moderate-to-high risk
(Class C) category. The principle seems sensible, as it is clearly the case
that some genetic tests pose greater risks than others. However, when
linked to the conformity assessment model, this distinction may create
problems, as tests in Class B are not subject to independent pre-
market review.
This could be a problem for a novel Class B test. The GHTF model
does not treat novelty as a risk factor. This is in contrast to the US
regulatory system, which treats novelty as a risk factor – novel tests are
automatically classified as Class III and subject to the most rigorous
conformity assessment route. This classification can be appealed, and
generally most new tests are reclassified as Class II, and subject to a less
rigorous pre-market review (de novo 510K, roughly equivalent to the
Class C conformity assessment route in the GHTF model). Experience
would suggest that lack of familiarity with a new test – whether it is
the testing platform, the biomarker/s, the interpretative algorithm or
any combination of these three – can lead to errors. The true
performance of a test, both its analytic and clinical validity, is not
known until the test has been in routine clinical practice for some
time. Furthermore, tests generally perform less well in routine use
than they do in clinical investigations. For these reasons, novel tests are
more likely to lead to incorrect results and so novelty should be
formally acknowledged as a risk factor.
Analytic and clinical validity. Most stakeholders believe that the
Directive requires manufacturers to provide evidence of a test’s
analytic validity, but only requires evidence of a test’s clinical validity
if clinical claims are made by the manufacturer.191 However, recent
discussion with a range of competent authorities has revealed that in
fact member states disagree about the scope of the Directive, with
some believing that it covers both analytic and clinical validity as
minimum requirements. An international comparison indicates diver-
gence between the US and Canadian systems and those of the EU and
Australia in this regard.
Clinical claims: MEDDEV guidance on Research Use Only (RUO)
products issued in 2004 highlights the issue of the distinction between
Country/region Analytic validity Clinical validity
USA Yes Yes
Canada Yes Yes
Europe Yes Unclear
Australia Yes Only if clinical claims made?
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research and clinical use. This guidance clearly states that an IVD test
with no intended medical purpose is not a test under the IVD
Directive, it is simply an RUO product:
In summary for a product to be categorized as an RUO product
it must have no intended medical purpose or objective. When a
medical purpose has been established based on sufficient and
broadly agreed upon scientific, diagnostic and clinical evidence,
then the product must comply with the requirements of the
Directive before the manufacturer can place it on the market
with an intended IVD use.262
It could be inferred that, in order to define a medical purpose, a
manufacturer would have to make a clinical claim (eg, by identifying
gene X, this test diagnoses disease Y), and if they make a clinical claim
then they must support it with evidence. It would seem that once a
manufacturer has a stated clinical purpose for a test, then they must
provide data on its clinical validity.
The intended clinical use: Finally, looking at the Directive require-
ments concerning safety and performance which all IVDs must
comply with before bearing CE marking and being placed on the
market, is it possible to fulfil the Directive’s essential requirements by
only providing data on a test’s analytic validity? GR Higson, a UK
expert on device regulation closely involved in the development of the
medical devices directives, commented on this issue, stating that:
final confirmation of the safety and performance of a medical
device is normally provided by observation of the behaviour
of the device in its intended use with patientsy Essential
requirements 1 and 6, and in some cases 3, can only be satisfied
by the evaluation of clinical data relating to the use of the
device.263
The first essential requirement states that the test must not ‘compro-
mise, directly or indirectly, the clinical condition or the safety of the
patients, the safety or health of users or, where applicable, other
persons’. Furthermore, it says that ‘any risks which may be asso-
ciated with their use must be acceptable when weighed against the
benefits to the patient and be compatible with a high level of
protection of health and safety’. One could argue that one can only
assess the benefits of a device in relation to an intended clinical
purpose. Risk assessment also requires knowledge of the clinical
purpose for the device. For IVD devices, one of the main risks are
the clinical consequences of an incorrect result. Since such incorrect
results might arise from either poor analytic validity or poor clinical
validity, it would appear logical that a comprehensive risk assessment
would include the evaluation of the clinical validity of the test for its
intended use.
Requirement three states that ‘the devices must be designed and
manufactured in such a way that they are suitable for the purposes
referred to in Article 1(2)(b), as specified by the manufacturer, taking
account of the generally acknowledged state of the art. They must
achieve the performances, in particular, where appropriate, in terms of
analytical sensitivity, diagnostic sensitivity, analytical specificity, diag-
nostic specificity, accuracy, repeatability, reproducibility, including
control of known relevant interference, and limits of detection, stated
by the manufacturer y’ Common usage of the terms analytical
sensitivity, diagnostic sensitivity, analytical specificity, and diagnostic
specificity would lead one to understand analytical sensitivity and
specificity as referring to analytic validity and diagnostic sensitivity
and diagnostic specificity as referring to clinical validity. However,
in the Commission Decision 2002/364/EC on common technical
specifications for IVD medical devices,264 the terms ‘diagnostic
sensitivity’ and ‘analytic sensitivity’ are defined thus:
To answer the debate on clinical validity, these definitions may need
to be re-visited in the future.
Predictive testing. At the April 2005 MDEG meeting, the IVD
Technical Group was asked to analyze the Directive in the context
of genetic testing. They produced a note on this issue for the
Competent Authorities. One of its conclusions addressed the question
of which genetic tests would be covered by the Directive. It stated that:
2. But, genetic tests that do not have a medical purpose, eg genetic
tests for forensic or predictive purposes, are not covered by the
Directive.’191
As most genetic tests can be used for both diagnostic and predictive
purposes, and a significant amount of genetic testing is predictive
rather than diagnostic, this conclusion may be highly significant.
Predictive applications include the prediction of late-onset disorders
such as Huntington’s disease, risk assessment for common, complex
diseases such as breast cancer and diabetes, prediction of response to
therapy (pharmacogenetics), and prognostic tests such as Agendia’s
MammaPrint test, which predicts the risk of breast cancer recurrence.
The intent of the Technical Group’s statement is unclear. Predictive
tests are currently covered by the Directive, as at least one test in
Annex II, List B, is predictive: ‘reagents fory evaluating the risk of
trisomy 21’. Furthermore, predictive tests meet the core requirements
for definition of a medical device, that is, they are ‘for the purpose of
diagnosis, prevention, monitoring, treatment or alleviation of disease’
and they also meet the definition of an IVD, that is, their purpose is
‘providing information concerning a physiological or pathological
state’. Manufacturers of predictive tests clearly think they are covered
by the Directive, as they are CE-marking them, for example, Roche
Amplichip and Agendia’s MammaPrint.
The IVD Technical Group recognizes that the text can be mis-
interpreted in this way and is currently analyzing the syntax of the
sentence, as the example given in the sentence is meant to refer to
genetic tests for non-medical predictive purposes.
Statutory post-marketing surveillance. Together with pre-market con-
trols, the EU legislative framework calls for active post-marketing
controls including post-market surveillance (PMS).
In general, there are three forms of post-market controls, one is for
surveillance of adverse events, the second is a more general aspect of
the quality assurance program that manufacturers must have in place,
and the third is market approval, whereby a product (such as a
medicinal product) is allowed on the market, but with additional and
systematic data collection, this might include a Phase IV trial in the
pharmaceutical sector.
In the past, device regulation, like the pharmaceutical legislation,
has tended to focus on pre-market review, but post-marketing
surveillance has taken on increasing importance in recent years. For
instance, when the Office of In Vitro Diagnostics was established in the
Food and Drug Administration (FDA), it united the pre-market and
post-marketing departments to establish a system for controlling the
total product lifecycle – from initial conception of a product through
(Diagnostic) sensitivity – The probability that the device gives a positive result in
the presence of the target marker.
Analytical sensitivity – In the context of the CTS it may be expressed as the limit
of detection: ie, the smallest amount of the target marker that can be precisely
detected.
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to its eventual obsolescence.265 In doing so, the FDA acknowledged
that because performance so often varies in clinical practice, it was
essential ‘to take an interest in how a device really works when it enters
the marketplace’.266
In Europe, the IVD Directive requires manufacturers to have a
systematic procedure to review experience gained from their devices in
the post-production phase. Ideally this should be part of the manu-
facturer’s quality system. Guidance from the European Association of
Notified Bodies indicates that the PMS system should be in place to
collect data on issues such as ‘changing performance trends [and]
performance in different use populations’.267 Another guidance, on
clinical evaluation in the post-marketing phase, indicates the impor-
tance of what it terms post-market clinical follow-up in certain critical
circumstances, which may be the severity of the disease, or the
innovative nature of the technology, that is, when ‘the design of the
device, the material, the principles of operation, the technology, or the
medical indication is new’.
The suggestion that the novelty of a device may be a trigger for
greater emphasis on PMS is also reflected in the Directive. Articles 10
and 11 include certain obligations on manufacturers to inform
competent authorities when they are introducing ‘new products’,
that is, if ‘there has been no such device continuously available on
the Community market during the previous three years for the
relevant analyte or other parameter’ or if ‘the procedure involves
analytical technology not continuously used in connection with a
given analyte or other parameter on the Community market during
the previous three years.’
Within the recitals to the Directive that speak to these articles,
particular reference is made to microarrays: ‘y this is true in
particular of high-density DNA probe devices (known as micro-
chips) used in genetic screening’. Such new products are subject to
special vigilance procedures, whereby any time in the first 2 years after
registration the competent authority ‘may at any time within the
following two years and on justified grounds, require the manufac-
turer to submit a report relating to the experience gained with the
device subsequent to its being placed on the market’. There is no
information available on how this provision has been used in practice.
FDA regulation
There are three relevant government institutions involved in oversight
of genetic tests in the United States, all contained in the Department of
Health and Human Services. The FDA oversees drug and device
licensing, including diagnostic test kits and reagents. The Center for
Disease Control (CDC) has a public health focus; its Division of
Laboratory Services develops guidelines and policies for diagnostic
testing and the Centers for Medicare and Medicaid Services
administer regulatory management of laboratory services and their
reimbursement.
Policy with regard to the use of genetics in health care has also been
shaped substantially in recent years by the activities of the National
Institutes of Health (NIH) and Department of Energy, following their
investments in the Human Genome Programme. A report on the
context of genetic testing in the United States, commissioned by the
NIH-Department of Energy working party on ethical, legal, and social
implications of human genome research in 1995 and published in
1998, highlighted the need for greater regulatory oversight of genetic
testing service. Following this, in 1998 the Clinical Laboratory
Improvement Advisory Committee in the CDC recommended that
the Clinical Laboratory Improvements Act should be updated to
establish specific regulations to address genetic testing, and in 1999
the Department of Health and Human Services Secretary’s Advisory
Group on Genetic Testing (SACGT – formed on the recommendations
of the 1998 Holtzman and Watson report)269 in turn called for greater
oversight. However, to date no new regulation has been agreed upon,
although the CDC is developing new guidelines.
In this context, the CDC initiated in 2004 the EGAPP project
with the objective of establishing and evaluating a systematic,
evidence-based process for assessing genetic tests and other appli-
cations of genomic technology in the transition from research to
clinical and public health practice.85 An EGAPP Working Group was
established in 2005, and its role involves establishing methods and
processes for evidence-based reviews on the evaluation of genomic
applications as well as the development of guidelines. The group has
commissioned evidence reviews on a number of tests and issued
its first recommendations at the end of 2007 (on the use of
CYP450 testing to guide the use of SSRIs in the treatment of adults
with depression).
Finally, the FDA established an Office of In Vitro Diagnostic Device
Evaluation and Safety270 in 2002 and since then has published several
guidelines regarding IVDs.271 Most relevant to this paper’s topic are
the guidelines on pharmacogenetic tests and genetic tests for heritable
markers (published in June 2007).272 The FDA have vacillated on the
issue of whether they have the authority to regulate in-house tests;
however, in the last 2 years, the agency has gradually begun to
intervene on a case-by-case basis in what it now terms ‘laboratory-
developed tests’. This piecemeal approach has now culminated in a
new draft FDA guidance in which the agency asserts that it has the
authority to regulate in-house tests as medical devices and indicates
that it is now intending to exercise that authority over a class of
complex tests that require interpretative algorithms to generate
results.273 The forthcoming SACGHS on oversight of genetic tests
recommends that FDA broaden its involvement in this area to address,
in some way, all laboratory-developed tests.
According to the SACGHS,274 clinical utility for clinical decision-
making is the balance between the benefits and harms of testing and
ensuing follow-up evaluation, treatment, or prevention (p 117).
Clinical utility must be evaluated within a specific context and utility
may vary, depending on the context and available alternatives. The
SACGHS report states: ‘The additional benefit or harm that would be
achieved by using the genetic test is called the incremental benefit or
incremental harm. These benefits and harms should be considered at
the individual, family, and societal levels’.
Claims will more typically relate to claims to quantify genetic risk.
SACGHS274 notes that avoidable false-positive or false-negative results
may occur if a test has not been subject to appropriate analytical
validation and that significant harms (real or potential) can occur if a
genetic test is used before its clinical validity is understood (pp 108–
111). For example: ‘In the event of false-positive test results, indivi-
duals may be exposed to an unnecessary battery of testing or
treatment. A false-negative test result could give false reassurance
regarding risk due to nongenetic causes or induce psychological effects
such as survivor guilt. False-negative results may delay diagnosis,
screening, and treatment’ (p 109). In order to assess clinical validity,
data must be provided on sensitivity, specificity, positive predictive
value, negative predictive value, etc. For multiple variants, a receiver
The PMCF plan can take the form of an extended follow-up of patients enrolled
in the pre-market trials, and/or a prospective study of a representative subset of
patients after the device is placed on the market. It can also take the form of
open registries.268
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operator curve can be calculated, provided the genetic architecture of
the disease is known (see, eg, Clayton69). The area under the curve
(AUC) provides a measure of the suitability of the test for use as a
screening test in the general population (see, eg, Jakobsdottir et al73).
OECD and clinical utility
The recent OECD Guidelines for Quality Assurance in Molecular
Genetic Testing,275 which outline the principles and best practice for
genetic testing, focus primarily on analytic validity and laboratory quality
assurance. However, the OECD Guidelines also state the following:
 Advertising, promotional and technical claims for molecular
genetic tests and devices should accurately describe the character-
istics and limitations of the tests offered (A.9).
 Laboratories should make available information on the analytical
and clinical validity of tests (A.ii).
 Laboratories should make available to service users current evi-
dence concerning the clinical validity and utility of the tests they
offer (B.vi).
 The interpretation of molecular genetic test results should be
appropriate to the individual patient and should be based on
objective evidence (D.4).
 Reports should be timely, accurate, concise, comprehensive, and
communicate all essential information to enable effective decision-
making by patients and healthcare professionals (D.ii).
The Annotations to the OECD Guidelines (paragraphs 34 and 35) add
the following:
 Information pertaining to the clinical validity and utility of a test
should be based on relevant existing medical guidelines and peer
reviewed literature and may include or be supplemented by in-
house studies appropriate for peer review. Sources of data should
be cited.
 An assessment of who should be offered the test is part of the
assessment of clinical validity.
 Measurements of validity include sensitivity, specificity, positive
predictive value, and negative predictive value.
 Clinical utility refers to the anticipated effect(s) of the clinical use
of the test result, including on health outcomes, recognising that a
variety of factors influence this outcome.
Council of Europe and clinical utility
In 2008, the Council of Europe adopted an Additional Protocol to the
Convention on Human Rights and Biomedicine, concerning Genetic
Testing for Health Purposes,276 that sets down principles relating to
the quality of genetic services, prior information and consent, and
genetic counselling. It lays down general rules on the conduct of
genetic tests, calling for measures to ensure that genetic services are of
appropriate quality: a quality assurance program implemented in each
laboratory; that laboratories are subject to regular monitoring; that
tests meet the generally accepted criteria of scientific validity and
clinical validity; and that the persons providing genetic services have
appropriate qualifications to enable them to perform their role in
accordance with professional obligations and standards. The specific
statement on clinical utility is very clear: ‘Clinical utility of a genetic
test shall be an essential criterion for deciding to offer this test to a
person or a group of persons.’
The protocol also deals with direct-to-consumer genetic tests, a
market that seems to be growing rapidly. It specifies the conditions in
which tests may be carried out on persons not able to consent. Also
covered are the protection of private life and the right to information
collected through genetic testing. Finally, the Protocol touches on
genetic screening. The protocol was adopted in May 2007 and opened
for signature in November 2009. Once signed, it will be legally binding
in international law.
The implications of intellectual property rights for susceptibility
testing and diagnostics
In spite of its stimulating effect on innovation, intellectual property
has also been suggested to potentially inhibit research as a result of the
proliferation of DNA patents,277 resulting in limited access to novel
treatments and diagnostics (eg, as a result of high licensing fees).278
This argument is particularly supported by cases where patent holders
make broad claims (eg, Oncomouse patent) or exert strict monopoly
rights (eg, Myriad Genetic holds several patents on the breast cancer
genes BRCA1 and BRCA2, and exerts strictly its monopoly rights, not
allowing testing of the genes outside its laboratory). Further evidence
in this direction is provided by a recent study indicating the negative
impact of patenting and licensing practices on diagnostic research and
testing carried out by clinical laboratories.278
Although some reports have argued that substantial empirical
evidence to support the potentially inhibitory effects of IPR on
research is still lacking,279 a wider concern with regard to diagnostic
tests remains, especially as emerging techniques allow the detection of
multiple mutations at a time (microarray-based tests) to diagnose
disease susceptibility or drug disposition.280 In this context, the
development of patent thickets (a situation where different owners
have overlapping patent rights requiring multiple licenses) could pose
a significant barrier. The emergence of new applications for pharma-
cogenomics may further complicate the situation.281
Recent evidence indicates that intellectual property rights may
present a significant barrier to pharmacogenomics research and the
development of related tests.282,283 The type of patents that may be
issued to protect such tests would likely cover combinations of
biomarkers associated with, for example, drug efficacy or response.
A proliferation of such patents could create major difficulties for
further development of diagnostics if the patented sequences are
associated with multiple phenotypes. In this case, it would be required
that several licenses are acquired prior to developing a particular test,
with serious cost implications.
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APPENDICES
A. ACCE – Criteria list for the evaluation of a genetic test
Source: http://www.cdc.gov/genomics/gtesting/ACCE/acce_proj.htm
For a detailed description of the issues in the questions, see Haddow and Palomaki.84
Element Component Specific question
Disorder/setting
1. What is the specific clinical disorder to be studied?
2. What are the clinical findings defining this disorder?
3. What is the clinical setting in which the test is to be performed?
4. What DNA test(s) are associated with this disorder?
5. Are preliminary screening questions employed?
6. Is it a stand-alone test or is it one of a series of tests?
7. If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are only
some tests performed on the basis of other results (series)?
Analytic validity
8. Is the test qualitative or quantitative?
Sensitivity 9. How often is the test positive when a mutation is present?
Specificity 10. How often is the test negative when a mutation is not present?
11. Is an internal QC program defined and externally monitored?
12. Have repeated measurements been made on specimens?
13. What is the within- and between-laboratory precision?
14. If appropriate, how is confirmatory testing performed to resolve false-positive results in a timely manner?
15. What range of patient specimens have been tested?
16. How often does the test fail to give a useable result?
17. How similar are results obtained in multiple laboratories using the same or different technology?
Clinical validity
Sensitivity 18. How often is the test positive when the disorder is present?
Specificity 19. How often is the test negative when a disorder is not present?
20. Are there methods to resolve clinical false-positive results in a timely manner?
Prevalence 21. What is the prevalence of the disorder in this setting?
22. Has the test been adequately validated on all populations to which it may be offered?
23. What are the positive and negative predictive values?
24. What are the genotype/phenotype relationships?
25. What are the genetic, environmental, or other modifiers?
Clinical utility
Intervention 26. What is the natural history of the disorder?
Intervention 27. What is the impact of a positive (or negative) test on patient care?
Intervention 28. If applicable, are diagnostic tests available?
Intervention 29. Is there an effective remedy, acceptable action, or other measurable benefit?
Intervention 30. Is there general access to that remedy or action?
31. Is the test being offered to a socially vulnerable population?
Quality assurance 32. What quality assurance measures are in place?
Pilot trials 33. What are the results of pilot trials?
Health risks 34. What health risks can be identified for follow-up testing and/or intervention?
35. What are the financial costs associated with testing?
Economic 36. What are the economic benefits associated with actions resulting from testing?
Facilities 37. What facilities/personnel are available or easily put in place?
Education 38. What educational materials have been developed and validated and which of these are available?
39. Are there informed consent requirements?
Monitoring 40. What methods exist for long-term monitoring?
41. What guidelines have been developed for evaluating program performance?
ELSI
Impediments 42. What is known about stigmatization, discrimination, privacy/confidentiality, and personal/family social issues?
43. Are there legal issues regarding consent, ownership of data and/or samples,
patents, licensing, proprietary testing, obligation to disclose, or reporting requirements?
Safeguards 44. What safeguards have been described and are these safeguards in place and effective?
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B. CHEC – Criteria list for systematic reviews on economic
evaluation studies
Source: Evers et al.165 2005 r Cambridge Journals, reproduced with permission. For a detailed
description of the issues in the questions, see http://www.beoz.unimaas.nl/chec.
C. Details on the systematic search
C1: Search strategy
Database: PubMed
Date of query: 25 July 2007
Database: Cochrane (including the databases of the Centre for Reviews
and Dissemination (CRD): DARE, NHS EED, HTA)
Date of query: 2 August 2007
C2: Studies identified
It needs to be noted that this overview only presents the base case
results calculated by the authors, without further assessment of
quality. Many of these results are subject to high uncertainty and
may underestimate the cost per health gain. For reviews discussing
these studies, see, for example, Carlson et al,163 Jarrett and Mugford,170
and Rogowski.153
Breast and ovarian cancer
Colorectal cancer
Familial hypercholesterolemia
1. Is the study population clearly described?
2. Are competing alternatives clearly described?
3. Is a well-defined research question posed in answerable form?
4. Is the economic study design appropriate to the stated objective?
5. Is the chosen time horizon appropriate to include relevant costs and
consequences?
6. Is the actual perspective chosen appropriate?
7. Are all important and relevant costs for each alternative identified?
8. Are all costs measured appropriately in physical units?
9. Are costs valued appropriately?
10. Are all important and relevant outcomes for each alternative identified?
11. Are all outcomes measured appropriately?
12. Are outcomes valued appropriately?
13. Is an incremental analysis of costs and outcomes of alternatives performed?
14. Are all future costs and outcomes discounted appropriately?
15. Are all important variables, whose values are uncertain, appropriately
subjected to sensitivity analysis?
16. Do the conclusions follow from the data reported?
17. Does the study discuss the generalizability of the results to other settings
and patient/client groups?
18. Does the article indicate that there is no potential conflict of interest of
study researcher(s) and funder(s)?
19. Are ethical and distributional issues discussed appropriately?
Search no. Query Results
1 Polymorphism, genetic[mesh] 104 421
2 Costs and cost analysis[mesh] OR economics[subheading] 264 416
3 Polymorphism, genetic[mesh] AND (costs and cost
analysis[mesh] OR economics[subheading])
225
Search no. Query Results
1 Polymorphism, genetic 362
2 Economics 183
3 Costs and cost analysis 2457
4 Polymorphism, genetic AND economics 12
5 Polymorphism, genetic AND costs and cost analysis 203
Study Result
Type of mutation
or condition
Balman˜a et al 284 h4,294/LYG BRCA
Brain et al 285 Additional $22.55 for an initial
specialist genetic assessment
(vs standard care)
BRCA
Elkin et al 286 $145000/QALY (FISH); $125 000/
QALY (Hercep Test+FISH)
HER2
Grann et al 287 $20 717/LYG BRCA
Heimdal et al 288 h832/LYG BRCA
Morelle et al 289 Dominateda HER2
Neyt et al 290 Bh50 000/LYG HER2
Norum et al 291 Not favorable HER2
Sevilla et al 292 $971.30/mutation detected BRCA
Tengs and Berry 293 o34 000/QALY BRCA
aAn intervention is dominated by an alternative that can be implemented in a more effective
way and at lower costs at the same time.
Study Result
Type of mutation
or condition
Bapat et al 294 $2568/family saved (CAN$ 3056) FAP
Breheny et al 295 AU$12 141–14 783/person saved HNPCC & FAP
Chikhaoui et al 296 Cost saving (vs clinical screening
without prior genetic testing)
FAP
Cromwell et al 297 $583/screened person saved FAP
Kievit et al 298 h2184/LYG HNPCC
Ramsey et al 299 $42 210/LYG (probands tested); $7556/LYG
(probands and siblings and children tested)
HNPCC
Ramsey et al 300 $11 865/LYG ($8005–$80 226/LYG)
(Bethesda guidelines treatment algorithm);
$35 617/LYG ($15 091–$180056/LYG) (MSI
testing to detect HNPCC carriers); $49 702/LYG
($19 100–$252 151/LYG) (DNA analysis for
Bethesda clinical positive points); $267
548/LYG ($68 328–$637007/LYG) (DNA
analysis for all)
HNPCC
Reyes et al 301 $6441/mutation detected HNPCC
Vasen et al 302 $12 577/LY HNPCC
Study Result
Type of mutation or
condition
Marang-van de
Mheen et al 303
h25 000–32000/LYG LDL receptor
Marks et al 304 Dominated (by cholesterol testing and
phenotype diagnosis)
LDL receptor
Marks et al 305 Dominated (by cholesterol testing and
phenotype diagnosis)
LDL receptor
Wonderling et al 306 $87 000/LYG (worst-case scenario:
$38 300/LYG)
LDL receptor
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Hemochromatosis
A recent study published after this review concluded that the cost
effectiveness of population screening for hereditary hemochromatosis
in Germany is about 124 000 and 161 000 EUR/LYG for phenotype
and genotype screening, respectively.145
Thrombotic disease
Diabetes mellitus
D. Nutrigenomics
D1: Search strategy
Database: PubMed
Date of query: 28 August 2007
Database: Cochrane (including the databases of the Centre for Reviews
and Dissemination (CRD): DARE, NHS EED, HTA)
Date of query: 28 August 2007
D2: Studies identified
Study Result
Type of mutation
or condition
Adams and Valberg307 Dominated (by phenotypic screening) HFE
Bassett et al 308* 4$669 savings per case detected HLA
El-Serag et al 133* $508–3665/LYG HFE
Gagne´ et al 309 Potentially cost saving HFE
Scho¨ffski et al 310 h4441/LYG HFE
Study Result
Type of mutation or condi-
tion
Auerbach et al 311 $11 100/QALY (positive
tested individuals treated
for 24 months)
FVL, prothrombin
(G20210A)+antithrombin
III+protein C+protein S,
homocysteinemia+lupus
anticoagulant
Creinin et al 312 $4 800 000/life year
(for a 20-year-old woman);
$7 100 000/life year
(for a 40-year-old woman)
FVL+activated protein C,
protein S+antithrombin III
deficiencies
Eckman et al 313 $16 823/QALY FVL+activated protein C
Marchetti et al 314 $13 624/QALY FVL+prothrombin
(G20210A)
Marchetti et al 315 $12 833/QALY FVL+prothrombin
(G20210A)
Study Result
Type of mutation or
condition
Hahl et al 316 Cost saving (vs repeated analy-
sis of markers of autoimmunity
in the entire population)
HLA-DQB1
(type 1 diabetes)
Search no. Query Results
1 Nutrigenomics 134
2 Costs and cost analysis[mesh] OR economics[subheading] 264 416
3 Nutrigenomics AND (costs and cost analysis[mesh] OR
economics[subheading])
1
Search no. Query Results
1 Nutrigenomics 1
2 Economics 183
3 Costs and cost analysis 2457
4 Nutrigenomics AND economics 0
5 Nutrigenomics AND costs and cost analysis 0
Study Details Source
Ronteltap
et al 317
Consumer acceptance of technology-based food
interventions
Supplementary
search
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Table 5 Direct-to-consumer (DTC) testing companies
Direct-to-consumer (DTC) testing companies
Company Tests offered Delivery model
23andMe Susceptibility testing for common diseases as well as
ancestry testing
DTC via internet
Acu-Gen Biolab, Inc. Fetal DNA gender test DTC via internet
Consumer genetics Fetal gender; caffeine metabolism; alcohol metabolism;
asthma drug response
DTC via internet
Cygene Direct Osteoporosis; athletic performance; glaucoma and
macular degeneration; thrombosis
DTC via internet
deCODE (Iceland) Susceptibility testing for cancers, diabetes, heart dis-
ease, osteoporosis, and Parkinson’s disease and others;
also ancestry testing
DTC via internet
Dermagenetics Skin DNA profile; custom skin cream DTC through spas and similar retailers
DNADirect a-1 antitrypsin deficiency; Ashkenazi Jewish carrier
screening; blood clotting disorders; breast and ovarian
cancer; colon cancer screening; cystic fibrosis; diabetes
risk; drug response panel; hemochromatosis; infertility;
recurrent pregnancy loss; tamoxifen
DTC via internet; genetic counsellors available by phone
G-Nostics (UK) Predisposition to nicotine addiction and response to
nicotine replacement products
DTC via internet and through pharmacies
Genelex Pharmacogenetics testing; celiac disease; hemochro-
matosis; gum disease; nutritional genetic testing; DNA
Diett consultation; weight loss system
DTC via internet
Genetic Health (UK) (tests are
performed by an Austrian test developer
and laboratory Genosense)
For males: genetic predisposition to prostate cancer,
thrombosis, osteoporosis, metabolic imbalances of
detoxification, and chronic inflammation
DTC via internet; most services include a medical
consultation
For females: genetic predisposition to breast cancer,
bone metabolism (osteoporosis), thrombosis, cancer, and
long-term exposure to estrogens
Nutrigenetic test: test for a range of genes that influence
nutritional processes such as lipid and glucose metabolism
Pharmacogenetic test: test for CYP450 genes, which
influence how the liver metabolizes a large number of
commonly prescribed drugs
Premium male gene/premium female gene: combine all
the other tests except the nutrigenetic one
Geneticom (Netherlands) Common disease risk Not clear
Genosense (Austria) Susceptibility tests Do not offer DTC tests themselves, but some of the
institutions they partner with to order tests for consumers
offer DTC testing (eg, Genetic Health in the United
Kingdom)
Graceful Earth Alzheimer (ApoE) DTC via internet
Health Tests Direct More than 400 blood tests, including a few genetic tests
(cystic fibrosis carrier screen, Factor V Leiden); others
may also be available by calling
DTC via internet
Health Check USA A wide range of laboratory tests, including the following
genetic tests: celiac disease; Factor V R2; Factor V
Leiden; hereditary hemochromatosis
DTC via internet; as additional service, the patient can
request interpretation by a board-certified physician; free
genetic counselling offered by Kimball Genetics for
physicians, patients, and families
Holistic Health Nutrigenomic test: comprehensive methylation panel
with methylation pathway analysis; company also sells a
variety of nutritional supplements
Not described
Kimball Wide range of well-established genetic tests DTC via internet, but detailed telephone consultation
with certified genetic counsellor is mandatory; report is
sent to the physician and the customer
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Table 5 Continued
Direct-to-consumer (DTC) testing companies
Company Tests offered Delivery model
MediChecks (UK) Wide range of well-established genetic tests, from Factor
V thrombosis risk to BRCA testing for breast cancer risk
(most tests are performed by the private pathology
laboratory TDL)
DTC via internet, but company recommends physician
referral for high-impact tests such as BRCA
Medigenomix (Germany) Thrombophilia and osteoporosis risk tests DTC via internet
Mygenome.com Alzheimer’s disease (genetic testing for common risk
factors); drug sensitivities (genetic tests for genes that
affect the safety and activity of many common pre-
scription and over-the-counter drugs); cardiovascular
disease (genetic tests differentiate treatable risk factors
for heart disease and stroke); thrombosis (genetic tests
identify risk factors for blood clots); pregnancy risk
(genetic tests identify risk factors for complications of
pregnancy); osteoporosis (genetic tests identify risk fac-
tors for osteoporosis and fractures)
Not clear
Navigenics Risk analysis for more than 20 common diseases, such
as prostate cancer and diabetes
DTC via internet
Quixtar Heart health; nutrigenic tests and supplements; also
sells dietary supplement
DTC via internet
Salugen Nutrigenic tests and supplements DTC sold through spas
Sciona Heart health; bone health; insulin resistance; antioxi-
dant/detoxification; inflammation
DTC via Internet
Smart Genetics Prediction of HIV progression to AIDS DTC via internet; free counselling available
Suracell DNA profile test that identifies inherited genetic aging
profile, and a biomarker assessment test that measures
DNA damage, oxidative stress, and free radical levels;
personal genetic supplements for DNA repair and
nutrition
DTC via internet
Source: Reproduced with permission of Annual Reviews, Inc. from Hogarth et al.192 Copyright r 2008 by Annual Reviews, Inc.; permission conveyed through Copyright Clearance Center, Inc.
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